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Abstract 
With the prevalence of obesity and metabolic syndrome rising sharply world-
wide, it has become increasingly important to define the molecular mechanisms 
underlying the pathogenesis and progression of diseases associated with lipid-induced 
cytotoxicity.  Cardiovascular disease, type-2 diabetes mellitus, and nonalchoholic fatty 
liver disease (NAFLD) have all recently gained recognition as diseases that are 
exacerbated by lipoapoptosis.  In this dissertation, we demonstrate a novel role for 
caspase-2 as an initiator of lipoapoptosis.  Using an unbiased metabolomics approach, 
we discovered that the activation of caspase-2, the initiator of apoptosis in Xenopus egg 
extracts, is associated with an accumulation of long-chain fatty acid (LCFA) metabolites.  
Metabolic treatments that block the buildup of LCFAs potently inhibit caspase-2, while 
add-back of a saturated LCFA restores caspase activation in the extract setting.  
Extending these findings to mammalian cells, we show that caspase-2 is engaged and 
activated in response to treatment with the saturated LCFA, palmitate.  Down-
regulation of caspase-2 significantly impairs cell death induced by saturated LCFAs, 
revealing a conserved, critical role for caspase-2 in mediating LCFA-induced 
lipoapoptosis.   
Since lipoapoptosis has been implicated as a key driver of the progression of 
NAFLD, we aimed to determine the therapeutic significance of our findings by 
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evaluating the importance of caspase-2 in an in vivo model of this disease.  We subjected 
wild-type and caspase-2 knockout mice to a diet which induces severe liver steatosis and 
the development of nonalcoholic steatohepatitis (NASH), the most advanced stage of 
NAFLD characterized by liver fibrosis.  Interestingly, we observed an increase in 
caspase-2 protein levels in the livers of wild-type mice fed a NASH-inducing diet.  These 
findings were of particular importance, since caspase-2 expression was also significantly 
elevated in patients diagnosed with NASH.  Most importantly, we demonstrated that 
caspase-2 knockout mice are protected from apoptosis and fibrosis when fed a NASH-
inducing diet, suggesting that caspase-2 is a major regulator of hepatocyte lipoapoptosis.  
Together, these findings reveal a previously unknown role for caspase-2 as an initiator 
of lipoapoptosis and suggest that caspase-2 may be an attractive therapeutic target for 
inhibiting pathological lipid-induced apoptosis.
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1. Introduction  
1.1 Apoptosis 
Apoptosis is a form of programmed cell death that is activated in response to 
pro-death stimuli.  Characterized by rapid cellular fragmentation and phagocytosis, 
apoptosis eliminates damaged or unneeded cells, while preserving the integrity of the 
surrounding tissue.  This energy-consuming process is defined by distinct molecular 
and morphological characteristics, including chromatin condensation, DNA 
fragmentation, membrane phosphatidylserine externalization, and plasma membrane 
blebbing.  Importantly, the intracellular contents of the dying cell are never exposed to 
the extracellular environment, but rather are excreted from the dying cell through 
membrane-enclosed apoptotic vesicles.  These vesicles, which pinch off from the dying 
cell as it blebs, are engulfed and disposed of by neighboring phagocytes and thus, do not 
elicit a host immune or inflammatory response. 
Apoptosis is critical for proper tissue development and homeostasis.  Under 
normal physiologic conditions, apoptosis of damaged or unneeded cells must be 
precisely balanced by cellular regeneration in order to maintain tissue structure and 
function.  Disruption of the apoptotic program can result in either excessive cell death or 
inappropriate cell survival.  Excessive cell death can lead to immunodeficiency or the 
development of chronic degenerative diseases, while inappropriate cell survival can 
manifest as cancer or autoimmunity.  Regardless of the disturbance, improper apoptotic 
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signaling can significantly compromise tissue function and thus, insight into the 
molecular mediators of this highly regulated process could be useful in conditions 
requiring therapeutic intervention.   
1.1.1 Apoptosis signaling cascade 
The apoptotic signaling cascade is mediated by a group of cysteine proteases 
known as caspases.  Synthesized as inactive zymogens, caspases can become activated 
following cellular insult through either oligomerization and/or proteolytic processing.  
Following their activation, caspases use a cysteine residue in their active site to cleave 
protein substrates at aspartic acid residues.  Cleavage of substrates can promote 
apoptosis in two ways: through the direct dismantling of the cell, or by promoting a 
feed-forward activation of the apoptotic signaling cascade.  Activation of this cascade is 
accomplished by either initiating additional pro-death signaling molecules or inhibiting 
antagonistic pro-survival pathways.   
Caspase proenzymes are classified as either initiator or executioner caspases 
based on their role in the apoptotic program.  Initiator caspases (e.g., caspases-2,-8, and -
9), which are important in upstream signaling, become activated through the binding of 
adaptor proteins to their prodomains.  This binding facilitates their oligomerization into 
high molecular weight protein complexes, which triggers their dimerization and 
processing into active enzymes.  Once active, initiator caspases activate executioner 
caspases (e.g., caspases-3 and -7) via proteolytic cleavage.  Executioner caspases then go 
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on to cleave protein substrates, leading to an organized dismantling of the cell and 
ultimately cell death (Figure 1.1).   
 
 
Figure 1.1: The apoptotic signaling cascade  
 
Surprisingly, little is known about how caspase-mediated cleavage of substrates 
promotes the characteristic morphological changes observed during apoptosis, 
including chromatin condensation, membrane phosphatidylserine externalization, and 
apoptotic body formation.  To date, over 700 caspase cleavage sites have been identified 
in more than 550 unique substrates, all of which have been experimentally validated 
(Fridman et al., 2013).  Despite our lack of clarity regarding cellular disassembly 
Figure 1.1: The apoptotic signaling cascade is initiated in response to pro-death stimuli.  
Apoptotic signaling results in the activation of initiator caspases, which oligomerize and 
undergo auto-catalytic cleavage to form mature, active enzymes.  Initiator caspases then go on to 
cleave and activate executioner caspases.  Executioner caspases cleave multiple cytosolic 
substrates, trigger the activation of nucleases, and breakdown structural components of the cells 
(i.e., lamins), leading to an organized dismantling of the cell and ultimately cell death. 
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processes, it is clear that the activation of caspases serves to amplify a pro-death signal, 
pushing the cell towards death via a complex network of signaling events.   
Apoptotic signaling pathways are initiated by either extracellular or intracellular 
stress signals.  Extracellular initiation, more commonly referred to as the extrinsic 
apoptotic pathway, results from the engagement of plasma membrane death receptors.  
These receptors, which become activated upon pro-death ligand binding, initiate 
downstream executioner caspase activation and apoptosis.  Conversely, intracellular 
stress cues result in activation of the intrinsic apoptotic pathway.  This pathway, which 
signals through the mitochondria, promotes the release of the mitochondrial respiratory 
chain protein, cytochrome c.  Cytosolic cytochrome c, in combination with other pro-
apoptotic proteins, triggers the activation of executioner caspases (Waterhouse and 
Green, 1999).  The similarities and differences between these two apoptotic pathways are 
discussed in detail below.   
1.1.1.1 Extrinsic pathway 
Activation of the extrinsic apoptotic pathway is regulated by pro-death ligand 
binding to extracellular death receptors, which triggers trimerization and activation of 
intracellular pro-apoptotic signaling (Figure 1.2).  For example, the family of tissue 
necrosis factor (TNF) receptors, which includes both TNF and Fas receptors, function as 
initiators of death.  Interaction of these receptors with their extracellular ligands, TNF 
and FasL respectively, results in clustering of the receptors at the plasma membrane 
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(Ogasawara et al., 1993; Suda et al., 1993; Tartaglia et al., 1993; Trauth et al., 1989).  In the 
case of Fas, binding of FasL to the receptor triggers a clustering event, which results in 
the recruitment of the intracellular Fas-associated death domain (FADD) protein, 
forming what is known as the death-inducing signaling complex (DISC) (Muzio et al., 
1996).   
 
Figure 2.2: The extrinsic apoptotic pathway 
 
Figure 1.2: The extrinsic apoptotic pathway is initiated at the plasma membrane by the 
binding of a ligand to its extracellular death receptor.  Ligand binding recruits the death-
induced signaling complex (DISC), which binds and activates the initiator caspase, caspase-8.  
Once active, caspase-8 can directly cleave effector caspases (caspase-3/-7) and/or the BH3-only 
protein Bid.  Cleavage of Bid forms truncated Bid (tBid), which can activate mitochondrial 
permeabilization by promoting the oligomerization of Bax and Bak. Mitochondrial 
permeabilization results in cytochrome c release, formation of the apoptosome, and activation 
of the initiator caspase, caspase-9.  Caspase-9 can then directly cleave and activate the 
executioner caspase, caspase-3. 
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DISC formation provides a platform for the recruitment and proximity-induced 
activation of caspase-8 (Kischkel et al., 1995).  Once active, caspase-8 can trigger the 
activation of the executioner caspases in either one of two ways; directly through 
cleavage of caspases-3 and -7 or indirectly through cleavage of the BH3-only protein Bid, 
which promotes mitochondrial permeabilization (the mechanistic signaling pathway is 
discussed further in the next section) (Li et al., 1998; Luo et al., 1998; Scaffidi et al., 1998).  
Interestingly, while the intrinsic apoptotic cascade relies entirely on mitochondrial 
signaling, the extrinsic pathway may or may not require mitochondrial feedback for 
amplification of cell death.  Regardless of whether the pathway utilizes mitochondrial 
cytochrome c release in the cell death process, classical apoptotic morphology is still 
observed; suggesting that activation of executioner caspases is truly what drives the 
cellular characteristics observed in apoptosis. 
1.1.1.2 Intrinsic pathway 
A variety of intracellular stresses have been shown to initiate the intrinsic 
apoptotic pathway, including hypoxia, oxidative stress, and DNA damage.  The 
activation of the intrinsic pathway is regulated by members of the Bcl-2 family of 
proteins, whereby pro-apoptotic BH3-only proteins (i.e., Bid, Bad, etc.) sequester anti-
apoptotic Bcl-2 proteins (i.e., Bcl-xL) away from Bax and Bak, allowing them to 
oligomerize.  The oligomerization of Bax and Bak induces mitochondrial outer 
membrane permeabilization (MOMP) through the formation of Bax/Bak pore and 
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enables the release of cytochrome c from the intermitochondrial space into the cytosol 
(Danial and Korsmeyer, 2004).  Once cytosolic, cytochrome c forms a multimeric 
complex with the apoptotic protease activating factor (Apaf-1), resulting in recruitment 
and activation of caspase-9 (Kluck et al., 1997; Liu et al., 1996; Ow et al., 2008).  This 
complex, termed the apoptosome, cleaves and activates the executioner caspases, 
caspase-3 and -7, which then dismantle the cell through substrate cleavage (Inoue et al., 
2009; Li et al., 1997b). 
Importantly, caspase-2 has been shown to function as an initiator caspase in the 
intrinsic apoptotic pathway, signaling upstream of the mitochondria to promote 
cytochrome c release (Figure 1.3) (Ho et al., 2008; Imre et al., 2012; Tu et al., 2006a).  The 
prevailing model is that caspase-2, once activated, cleaves the BH3-only protein Bid to 
generate truncated Bid (tBid).  tBid then activates Bax to promote cytochrome c release 
(Bonzon et al., 2006; Guo et al., 2002).  Amplification of the intrinsic apoptotic pathway 
relies heavily on MOMP, since activation of the executioner caspase, caspase-3, can 
feedback to promote cleavage and direct activation of caspase-2 to further propagate 
apoptotic signaling (Li et al., 1997a; Swanton et al., 1999). 
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Figure 3.3: The intrinsic apoptotic pathway 
 
1.2 Caspase-2 
Caspase-2 is the most apical initiator caspase involved in the intrinsic apoptotic 
cascade.  Since its initial discovery more than twenty years ago, caspase-2 has been 
identified in the literature by a number of names, including Nedd-2 (neural precursor 
Figure 1.3: The intrinsic apoptotic pathway is activated in response to intracellular stress and 
results in the activation of the initiator caspase, caspase-2.  Caspase-2 cleaves the BH3-only 
protein Bid, forming truncated Bid or tBid. tBid can activate mitochondrial permeabilization 
through modulation of bcl-2 proteins at the mitochondria, including the pro-apoptotic 
proteins, Bax and Bak. Anti-apoptotic bcl-2 family members (Bcl-2, Bcl-xL) antagonize the 
oligomerization and activation of Bax/Bak, controlling mitochondrial cytochrome c release. 
Once cytosolic, cytochrome c can induce the oligomerization of Apaf-1, forming a large, 
heptameric complex, known as the apoptosome.  The apoptosome recruits and activates the 
initiator caspase, caspase-9, which can directly cleave and active the executioner caspases, 
caspase-3 and -7.   Executioner caspases can cleave a number of cellular substrates leading to 
cell death or they can cleave caspase-2 in a positive feedback loop to promote amplification of 
the apoptotic signaling cascade.   
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cells-expressed, developmentally downregulated) and ICH-1 (interleukin-1 converting 
enzyme/C. elegans cell death gene (ICE/CED-3) homolog 1) (Kumar et al., 1994; Kumar et 
al., 1992; Wang et al., 1994; Yuan et al., 1993).  Interestingly, caspase-2 is the most 
evolutionarily conserved of all the caspases, suggesting that the structure and function 
of this enzyme are so important that it needed to be greatly maintained, despite the 
evolution of species.   
Highly conserved proteins are often thought to be required for basic cellular 
function, such that the loss of the protein would be developmentally detrimental to the 
survival of the organism.  Despite sharing 43% amino acid identity with its C. elegans 
homolog, CED-3, caspase-2 is not required for proper embryonic development.  For 
example, caspase-2 knockout (KO) mice are developmentally normal, showing only a 
mild apoptotic phenotype in female germ cells (Bergeron et al., 1998).  This phenotype is 
due to a loss of apoptosis that occurs during normal ovary development.  Briefly, the 
female ovary undergoes a substantial clonal expansion of oocytes during normal 
embryonic development.  Since the ovary simply cannot sustain such a large number of 
germ cells, nearly 1/2 to 2/3 of the oocytes produced undergo apoptosis late in gestation 
(Ratts et al., 1995; Tilly et al., 1997).  Oocytes from caspase-2 KO mice fail to undergo this 
elimination process and thus, female mice are born with an excess number of oocytes 
(Bergeron et al., 1998).   
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In addition to this mild germ cell phenotype, recent data has revealed that 
caspase-2 KO mice also suffer from an enhanced aging phenotype.  Notably, the loss of 
caspase-2 is associated with a shortened maximum lifespan, impaired hair growth, 
increased bone loss, and reduced body fat content (Zhang et al., 2007).  All of these traits 
are commonly observed in the setting of premature aging and suggest that caspase-2 
may play a role in protecting animals from aging.  Remarkably, this study was the first 
to link caspase-2 to an age-related phenotype and suggests that additional studies 
should be performed to determine how a pro-apoptotic gene could influence such a 
complex biological process (Zhang et al., 2007).   
1.2.1 Caspase-2 structure 
The structure of caspase-2 is similar to other initiator caspases in that it contains 
a large amino-terminal prodomain, followed by a large subunit and small subunit.  The 
prodomain of caspase-2 serves as a binding site for protein-protein interactions, while 
the large and small subunits combine to form the active enzyme.  The prodomain of 
caspase-2 contains a caspase recruitment domain (CARD) motif, which is used to bind 
other CARD-containing proteins in a homotypic interaction.  The CARD domain of 
caspase-2 is believed to facilitate its activation by triggering dimerization with CARD-
containing adaptor proteins (Kumar et al., 1997; Kumar et al., 1994; Wang et al., 1994).  
This activation process is similar to other well-characterized initiator caspases, including 
caspase-8 and -9, which are believed to exist as monomers in solution, becoming 
  
11 
dimerized only after ligand binding and engagement (Renatus et al., 2001; Talanian et 
al., 1996).   
Interestingly, the crystal structure of human caspase-2 suggests that the 
proenzyme can also exist in solution as a stable dimer.  Caspase-2 proenzymes were 
observed to bind in vitro in the absence of adaptor protein regulation, forming a covalent 
disulfide bond across the dimer interface that helps to both stabilize the protein pair and 
promote enzyme activation (Baliga et al., 2004; Schweizer et al., 2003).  Although 
formation of this disulfide bond can increase the catalytic efficiency of the enzyme, 
additional in vitro studies have revealed that the formation of this bond is dispensable 
for caspase-2 activation (Baliga et al., 2004).  It is still yet to be determined whether 
caspase-2 proteins can dimerize independently of adaptor protein regulation in vivo and 
thus, the prevailing mechanism of caspase-2 activation is via adaptor-protein mediated 
dimerization (Note: The mechanism of caspase-2 activation will be discussed in greater 
detail in section 1.2.2).  
1.2.2 Caspase-2 localization 
Caspase-2 differs from other caspase family proteins in its unique subcellular 
distribution.  For example, while the majority of caspases have been shown to be 
primarily cytoplasmic, caspase-2 can be found in nearly every cellular compartment, 
including the cytoplasm, nucleus, Golgi complex, endoplasmic reticulum (ER), and the 
mitochondria (Cheung et al., 2006; Mancini et al., 2000; Susin et al., 1999; van Loo et al., 
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2002; Zhivotovsky et al., 1999).  The nuclear localization of caspase-2 is regulated by the 
nuclear localization signal (NLS) located within its prodomain (Colussi et al., 1998).  The 
NLS interacts with the nuclear import proteins, /-importin, to facilitate its transport 
into the nucleus (Baliga et al., 2003; Colussi et al., 1998; Shikama et al., 2001).  The 
functional relevance of caspase-2 nuclear localization is not well understood and the 
mechanism of its nuclear export is still unknown.   
The localization of caspase-2 at ER membranes has been demonstrated by both 
immunofluorescence and membrane fractionation studies (Cheung et al., 2006).  
Interestingly, studies visualizing the activation of caspase-2 have shown that it can be 
activated in a perinuclear membrane region, similar to the ER (Bouchier-Hayes et al., 
2009).  These findings are of particular importance, as caspase-2 has recently gained 
recognition as an initiator of ER stress-induced apoptosis in a number of cellular settings 
(Gu et al., 2008; Penna et al., 2012; Uchibayashi et al., 2011; Upton et al., 2012).  It is 
tempting to hypothesize that caspase-2 is localized to the ER in order to activate ER-
stress-induced apoptosis.  Although this idea is an attractive one, it appears that there 
may be more to the story, as at least one recent publication has provided evidence that 
caspase-2 can play a role in the modulation of ER stress (Nemcova-Furstova et al., 2013).  
This paper demonstrated that the loss of caspase-2 could dampen the ER stress response 
elicited by saturated fatty acids in pancreatic islet β-cells (Nemcova-Furstova et al., 
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2013).  Thus, regardless of its influence on apoptotic signaling, subcellular distribution of 
caspase-2 at the ER may ready the enzyme for ER stress-induced activation.   
Since membrane and protein trafficking can occur simultaneously between the 
ER and the Golgi complex, it is perhaps not surprising that caspase-2 has also been 
shown to localize to the Golgi (Mancini et al., 2000; O'Reilly et al., 2002).  This subcellular 
fraction of caspase-2 has been shown to play a role in Golgi complex disassembly during 
apoptotic cell death by cleaving the structural support protein, golgin-160 (Mancini et 
al., 2000).  Although other caspases have been shown to cleave golgin-160, caspase-2 is 
the only one that has been shown to be localized at the Golgi complex in healthy, living 
cells (Mancini et al., 2000; O'Reilly et al., 2002).   
Although caspase-2 was initially shown to be localized to the mitochondria, 
subsequent studies have had difficulty replicating these findings.  The original 
publication provided evidence that the proenzyme form of caspase-2 could be localized 
to the mitochondrial intermembrane space (Susin et al., 1999).  It was suggested that 
caspase-2 is released to the cytoplasm following MOMP and that this would enable its 
interaction with cytoplasmic adaptor proteins and facilitate its activation (Susin et al., 
1999).  Numerous follow-up studies have failed to observe such an event, including a 
detailed mitochondrial fractionation study which assessed the release of several well-
established mitochondrial molecules (i.e., cytochrome c, SMAC/DIABLO) following 
apoptotic initiation (van Loo et al., 2002).  Due to this fact, the mitochondrial localization 
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of caspase-2 is the most controversial of its putative subcellular localization sites and 
most of the studies published to date favor the idea that caspase-2 is not a 
mitochondrially-localized factor (van Loo et al., 2002).   
1.2.3 Caspase-2 mechanism of activation 
Similar to other well-characterized initiator caspases, including caspase-8 and 
caspase -9, caspase-2 is activated by proximity-induced dimerization.  Dimerization is 
the key event required to activate caspase-2.  Although not required for catalytic activity, 
auto-processing of the enzyme at aspartic acid residue 333, promotes enzyme 
stabilization and enhancement of its activity (Baliga et al., 2004; Butt et al., 1998; Read et 
al., 2002).  As discussed in the previous section, caspase-2 can exist in solution as a 
dimer.  However, dimerization of caspase-2 proenzymes in the absence of adaptor 
protein regulation has failed to be demonstrated in vivo.  Thus, the prevailing 
mechanism is that caspase-2 is activated via the binding of adaptor proteins to its 
prodomain.  This binding, which facilitates its oligomerization into a high molecular 
weight complex, triggers its dimerization and auto-catalytic processing into an active 
enzyme.  Once activated, caspase-2 cleaves and activates the pro-apoptotic Bcl-2 family 
member, Bid, which in turn promotes Bax translocation to the mitochondria and 
cytochrome c release (Bonzon et al., 2006; Guo et al., 2002).   
Although canonically, caspase-2 is believed to be activated by proximity-induced 
dimerization, a second potential mechanism of caspase-2 activation has been described, 
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whereby caspase-3 mediates the cleavage and activation of caspase-2 (Li et al., 1997a; 
Swanton et al., 1999).  This secondary mechanism of activation is often thought to 
function as a feed-forward activation of the apoptotic signaling cascade, promoting 
further activation of caspases in order to enhance cell death.  This feed-forward circuitry 
has been shown to be required for cell death, since the low levels of caspase-3 activated 
by a single cell death pathway are not sufficient for apoptotic execution (Swanton et al., 
1999).   
1.2.3.1 Potential activation platforms 
As mentioned previously, caspase-2 is believed to be activated through the 
binding of adaptor protein complexes to its prodomain.  The most well-characterized 
activation complex for caspase-2 has been termed the “PIDDosome” and it is composed 
of the CARD and death domain (DD)-containing protein, RAIDD, and the p53-inducible 
DD-containing protein, PIDD (Tinel and Tschopp, 2004).  This complex, which has been 
shown to be responsive to DNA damage, is activated by the p53 mediated upregulation 
of PIDD expression (Lin et al., 2000).   
The structural assembly of the PIDDosome has been well studied, with 
crystallography studies showing that five PIDD and seven RAIDD molecules comprise 
the core of this complex, in a structure similar to the caspase-9 activating platform, the 
apoptosome (Park et al., 2007a).  Despite such comprehensive structural work, the 
significance of this platform has been challenged by genetic experiments showing that 
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PIDD is dispensable for the activation of caspase-2 in vivo (Kim et al., 2009; Manzl et al., 
2009).  Interestingly, RAIDD has been shown to be required for caspase-2 activation, 
even in settings where PIDD has been shown to be dispensable, suggesting that RAIDD 
may play a more central role in mediating caspase-2 oligomerization (Ribe et al., 2012).  
Nevertheless, these studies imply that alternative modes of caspase-2 activation must 
exist beyond the PIDDosome.   
One such alternative mechanism for caspase-2 activation is the DISC, an extrinsic 
apoptotic signaling complex that functions to activate caspase-8 in response to 
extracellular death stimuli.  Multiple studies have demonstrated that the proenzyme 
form of caspase-2 can be recruited to and activated by the DISC in response to DNA 
damage (DNA damage upregulates the expression of the CD95 death receptor, 
promoting clustering at the plasma membrane) (Lavrik et al., 2006; Olsson et al., 2009).  
Activation of caspase-2 by this platform is dependent upon caspase-8, such that the two 
enzymes must interact to facilitate cleavage of caspase-2 by caspase-8 (Olsson et al., 
2009).  While these observations provide an alternative activation platform for caspase-2, 
it is not known whether this platform can be triggered in the absence of DNA damage, 
which would make it a more general signaling platform, capable of initiating cell death 
in response to a variety of intracellular stressors.   
Two additional caspase-2-containing complexes have been cited in the literature, 
one of which includes its interaction with the serine/threonine-protein kinase 1 (RIP1) 
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and the TNF receptor associated factor 2 (TRAF2).  This complex, which has been 
implicated in the activation of pro-survival signaling pathways, such as NF-κB and p38 
MAPK, does not require the catalytic activity of caspase-2 to elicit these responses 
(Lamkanfi et al., 2005).  Unfortunately, the formation of this complex has only been 
demonstrated in overexpression settings or upon prolonged incubation of lysates at 
37°C, and thus the physiological relevance of this complex is still undefined.  Another 
putative caspase-2-containg complex was shown to consist of RAIDD, RIP1, TRADD, 
and the TNF-R1.  Although over-expression studies have demonstrated that caspase-2 
can form a complex with these proteins, evidence for endogenous complex formation 
still remains elusive (Ahmad et al., 1997).  Therefore, since little evidence has been 
presented to suggest that either of these complexes can form in response to physiological 
stimuli, their involvement in caspase-2 activation remains strictly speculative.   
1.2.3.2 Proximity-induced autocatalytic processing 
As mentioned briefly, caspase-2 dimerization is the key event required for its 
activation.  Following dimerization, caspase-2 undergoes proximity-induced 
autocatalytic processing and cleaves itself at three well-conserved aspartic acid residues.  
The first cleavage separates the large (p19) and small (p14) subunits of the enzyme via 
cleavage of aspartic acid residue 333.  These subunits remain stably associated and form 
the catalytic or active site of the mature enzyme.  The prodomain is then removed by 
cleavage of aspartic acid residue 169 and finally, the linker portion of the small subunit 
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is removed by cleavage of aspartic acid residue 347.  The fully mature caspase-2 enzyme 
is a heterodimer consisting of two large subunits (p19) and two small subunits (p12) 
(Figure 1.4).   
 
Figure 4.4: Mechanism of caspase-2 processing 
 
 
Figure 1.4: Procaspase-2 monomers are recruited into close proximity via adaptor protein 
interactions (e.g. RAIDD, PIDD).  Once in close proximity, caspase-2 proteins can dimerize, 
forming a partially active enzyme.  The catalytic domains of caspase-2 dimers can promote 
auto-catalytic cleavage between the large and small subunits of each monomer (at D333).  This 
cleavage results in stabilization of enzyme activity and promotes additional cleavages to 
remove the prodomain and linker region of the small subunit.  The fully processed enzyme is 
a stable tetrameric complex with maximal enzymatic activity. 
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It is important to note that the proximity-induced processing of caspase-2 is not 
required for its activation, since a non-cleavable mutant is still able to maintain catalytic 
activity toward its substrates (Baliga et al., 2004).  Cleavage of caspase-2 appears to be 
required for stabilization of its enzymatic activity, following initial activation.  Thus, the 
current model is that caspase-2 activation in triggered solely by dimerization and that 
the proximity-induced processing of the proenzyme occurs secondary to its 
oligomerization (Baliga et al., 2004).  The distinction between these two biochemical 
mechanisms is important, since many publications use caspase-2 processing as a readout 
of enzymatic activation.  Perhaps a more appropriate method for measuring caspase-2 
activation would be to evaluate enzyme dimerization or cleavage of a caspase-2-specific 
substrate.   
1.2.4 Caspase-2 activating stimuli 
Caspase-2 has been implicated in the induction of cell death by a number of 
cellular stressors, including DNA damage, neuronal stress, cytoskeletal disruption, and 
ER stress, among others (Table 1.1).  While this list is not exhaustive, it does suggest that 
there are only a limited number of cellular conditions in which caspase-2 can function as 
an initiator of cell death.  Our group, in addition to others, has found that caspase-2 
dependency can be both cell-type and stimulus specific, making it difficult to identify 
cellular stressors that universally engage caspase-2.  Because of these inconsistencies, 
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there has been much debate over caspase-2 activating stimuli and the contribution of 
caspase-2 to cell death in these scenarios.  
Table 1.1: Examples of stimuli that have been reported to activate caspase-2 
Stimulus Examples Cell Type Caspase-2 Activity 
Assessment 
References 
DNA damage Etoposide Jurkat, 
IMR90E1A, Hela 
Cleavage, siRNA, 
VDVAD-fmk, 
VDVADase, BiFC 
(Bouchier-Hayes et al., 2009; 
Franklin and Robertson, 2007; 
Lassus et al., 2002; Robertson 
et al., 2002) 
Cisplatin LLC-PK1, Caov4 VDVAD-fmk, 
VDVADase, 
cleavage, siRNA 
(Seth et al., 2005; 
Vakifahmetoglu et al., 2008) 
5-FU HCT116 VDVAD-fmk, 
VDVADase, 
siRNA 
(Vakifahmetoglu et al., 2006) 
Doxorubicin Mouse oocytes Oocyte survival 
 
(Bergeron et al., 1998) 
γ-irradiation HEK293, 
thymocytes, 
zebrafish 
embryos 
bVAD pulldown, 
cleavage, c2 
morpholino 
 
(Fushimi et al., 2008; O'Reilly 
et al., 2002; Shi et al., 2009) 
Daunorubicin H1299 VDVAD-fmk, 
siRNA 
(Baptiste-Okoh et al., 2008) 
UV HCT116 Cleavage 
 
(He et al., 2004) 
Cytoskeletal 
disruptors 
Zoledronic 
acid 
MEF Caspase2 KO MEF 
resistance 
(Ho et al., 2008) 
Cytochalasin 
D 
MEF, Hela Caspase2 KO MEF 
resistance, BiFC 
(Bouchier-Hayes et al., 2009; 
Ho et al., 2008) 
Vincristine MEF, Hela Caspase2 KO MEF 
resistance, BiFC 
(Bouchier-Hayes et al., 2009; 
Ho et al., 2008) 
Paclitaxel MEF, MCF-7,  
SK-BR-3 
Caspase2 KO MEF 
resistance, 
Cleavage, 
VDVADase, 
siRNA 
(Ho et al., 2008; Jelinek et al., 
2013) 
Neuronal 
stress 
β-amyloid Hippocampal 
neurons, 
sympathetic 
neurons, PC12 
Cleavage, 
Caspase-2 KO cell 
resistance 
(Troy et al., 2000) 
Transient 
global 
ischemia 
hippocampal 
CA1 neurons 
Cleavage (Niizuma et al., 2008) 
Hypoxia SK-N-MC, Cleavage, (Araya et al., 1998; Carlsson et 
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Neonatal rat 
brain 
Caspase-2 KO cell 
resistance, siRNA 
al., 2011; Carlsson et al., 2012) 
NGF 
Withdrawal 
Neuronal PC12 
cells, 
sympathetic 
neurons 
Cleavage, 
Antisense 
(Stefanis et al., 1998; Troy et 
al., 1997) 
NGF 
 
Mature 
oligodendrocytes 
Cleavage (Gu et al., 1999) 
ER Stress Brefeldin A Bax/Bak deficient 
MEF, Hela 
Cleavage and 
siRNA 
(Cheung et al., 2006; Upton et 
al., 2008; Upton et al., 2012) 
Tunicamycin U937, Hela Cleavage, 
VDVADase, 
siRNA 
(Cheung et al., 2006; Huang et 
al., 2009) 
Bortezomib Human myeloma 
(H929, 8226/S) 
siRNA, VDVAD-
fmk 
(Gu et al., 2008) 
Sorafenib U937 siRNA (Rahmani et al., 2007) 
Miscellaneous Oxidative 
Stress (ROS) 
U937, CEM, 
Neural stem cells 
Cleavage, siRNA 
VDVADase, 
VDVAD-fmk 
(Peart et al., 2003; Rosato et al., 
2008; Tamm et al., 2008) 
Death 
Receptor 
Activation 
Jurkat, HCT116, 
SKW6.4, U937, 
Human 
fibroblasts, Hela 
siRNA, Cleavage, 
VDVADase, BiFC 
(Berube et al., 2005; Bouchier-
Hayes et al., 2009; Wagner et 
al., 2004) 
Heat Shock Mouse 
splenocytes, 
Jurkat, Hela 
bVAD pulldown, 
BiFC 
(Bouchier-Hayes et al., 2009; 
Tu et al., 2006b) 
Metabolic 
Stress 
Xenopus oocytes 
and eggs 
Cleavage, 
VDVADase 
(Nutt et al., 2005) 
Note: This table has been adapted from Bouchier-Hayes (2010).  
 Importantly, caspase-2 activation can be assessed by a number of different 
assays, many of which have been annotated for the caspase-2 activating stimuli listed in 
Table 1.1.  The differences among these methodologies have contributed to the 
controversy surrounding caspase-2-activating stimuli and highlight the need for a more 
streamlined assessment of caspase-2 activation.  For example, many of the published 
papers use fluorogenic substrates or inhibitors based on the preferred substrate cleavage 
site for caspase-2 (VDVAD).  The problem with using such indicators is that they are not 
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specific for caspase-2, also being efficiently cleaved by executioner caspases, such as 
caspase-3 (McStay et al., 2008).   Proteolytic processing is also used as a common read-
out of caspase-2 activation.   As discussed previously, cleavage is not required for 
caspase-2 activation and can sometimes occur as a secondary consequence of apoptotic 
signaling, serving as a positive feedback loop to amply caspase activity (Baliga et al., 
2004; Li et al., 1997a; Swanton et al., 1999).  Thus, it can be difficult to interpret 
conclusions that are based solely on measuring caspase-2 cleavage by western blot.  
Another tool that is widely used to study caspase-2 activation is transient 
silencing via siRNA.  Aside from the potential off-target effects of siRNA-target 
sequences, this approach is probably one of the best ways to determine whether a cell 
depends upon caspase-2 for cell death.  Similar studies can also be performed using cells 
derived from caspase-2 KO mice.  Such investigations could confirm the necessity of 
caspase-2, while at the same time ruling out the contribution of positive feedback loops.  
While inconsistencies between siRNA and KO cell experiments may arise, they do not 
immediately rule out caspase-2 as an initiator of cell death.  There are a number of 
reasons why differences between these two approaches may arise.  For example, the 
expression of caspase-2 and/or its regulatory factors may differ between transient and 
stable KO settings or there may be differences in caspase-2 requirements in humans 
versus mice.  Moreover, there could be possible compensatory mechanisms in caspase-2 
KO mice that could mask the true function of caspase-2.  Because of these differences, 
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experiments that utilize transient silencing of caspase-2 can be useful in identifying 
functions of the enzyme that can be concealed in the KO setting.   
Due to the difficulty in assessing caspase-2 dependency and activation, research 
on this enigmatic caspase has remained challenging.  Going forward, biochemical and 
genetic assessments should be used combinatorially to determine the contribution of 
caspase-2 to stimulus-induced cell death.  Studies should also be performed in multiple 
cell types to determine the true contribution of caspase-2 to cell death across a broad 
range of tissue types. 
1.2.5 Caspase-2 regulation 
In addition to adaptor protein binding, transcriptional, translational, and post-
translational regulation of caspase-2 provides further control of apoptotic initiation.  The 
amount and accessibility of caspase-2 protein can significantly influence its activation 
status following cellular insult.  Importantly, caspase-2 protein levels have been shown 
to be transcriptionally regulated by p53, as well as post-transcriptionally by microRNAs 
(Baptiste-Okoh et al., 2008; Upton et al., 2012).  Post-translational regulation of caspase-2 
has also been shown to influence activation, serving to inhibit or, less commonly, 
activate the enzyme through changes in protein modifications (Andersen et al., 2009; 
Nutt et al., 2005; Shin et al., 2005; Yi et al., 2011).  These additional modes of caspase 
regulation are often influenced by cellular stress and can therefore, provide an added 
level of control to avoid inappropriate caspase-2 activation. 
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1.2.5.1 Transcriptional and translational regulation  
Caspase-2 levels have been shown to be regulated at the transcriptional level by 
a p53/p21-dependent pathway (Baptiste-Okoh et al., 2008).  The induction of p53 in 
damaged cells results in a reduced level of caspase-2 mRNA and protein.  This negative 
regulation of caspase-2 may be indirectly mediated by p53 through the induction of p21, 
since expression of the p21 transcription factor is sufficient to mediate the transcriptional 
repression of caspase-2 (Baptiste-Okoh et al., 2008).  Interestingly, the p53-mediated 
downregulation of caspase-2 was reported to occur in both damaged and non-
stimulated cells and may, therefore, serve as an apoptotic break in healthy cells to 
prevent an inappropriate activation of cell death signaling.  Although this type of 
regulation may seem counterintuitive for apoptotic cells, it may well be that this 
apoptotic break can be overcome once DNA damage reaches a certain threshold.    
Recent findings have also demonstrated that caspase-2 protein levels can be 
regulated at the post-transcriptional level by microRNAs.  This pathway, which was 
uncovered in the setting of ER stress, identified four distinct microRNAs that normally 
repress caspase-2 mRNA translation, miR-17, -34a, -96, and -125b (Upton et al., 2012).  
These microRNAs bind to the 3’ end of caspase-2 mRNA sequences and inhibit gene 
expression by blocking mRNA translation.  Interestingly, during periods of ER stress, 
the dual endoribonuclease and kinase, inositol requiring enzyme 1 alpha (IRE1α), 
reduces the levels of these mircoRNAs through RNA cleavage (Upton et al., 2012).  This 
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lifts the block on caspase-2 translational repression, resulting in increased expression of 
the protease.  Increased expression of caspase-2 then contributes to apoptotic cell death 
through proteolytic cleavage of Bid, which causes cytochrome c release from 
mitochondria. 
1.2.5.2 Post-translational modification 
In addition to protein level changes, caspase-2 activation can also be influence by 
post-translational modifications.  To date, caspase-2 has been shown to be post-
translationally modified by phosphorylation and n-terminal acetylation (Andersen et al., 
2009; Nutt et al., 2005; Shin et al., 2005; Yi et al., 2011).  Our group has specifically 
identified two independent phosphorylation sites on caspase-2, one in the prodomain 
and one in the linker region of the small subunit.   
Caspase-2 prodomain phosphorylation occurs on serine 135 (Xenopus 
numbering) and is catalyzed by the calcium/calmodulin-dependent protein kinase type 
II (CaMKII) (Nutt et al., 2005).  Interestingly, in cell-free Xenopus egg extracts, this 
phosphorylation has been shown to be regulated by metabolism, whereby abundant 
nutrient flux through the pentose phosphate pathway stimulates the activation of 
CaMKII via the production of coenzyme A (CoA) (McCoy et al., 2013; Nutt et al., 2005).  
This phosphorylation inhibits the binding between caspase-2 and its adaptor protein, 
RAIDD, and thus functions as an inhibitory phosphorylation on caspase-2 (Figure 1.5).   
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Figure 5.5: Metabolic regulation of caspase-2 by phosphorylation 
 
Caspase-2 is also suppressed by phosphorylation of the linker region of the small 
subunit.  This phosphorylation, which occurs on serine 308 (Xenopus numbering), is 
catalyzed by the M phase-promoting kinase, cyclin dependent kinase-1 (Cdk1) 
(Andersen et al., 2009).  Upon entering mitosis, the Cdk1-cyclin B1 complex 
phosphorylates caspase-2 and inhibits its activation by an unknown mechanism.  This 
phosphorylation may serve as a sort of cross-talk between apoptotic and cell cycle 
machineries, ensuring that apoptosis is not activated during normal cell cycle 
progression (Andersen et al., 2009). 
Figure 1.5: Caspase-2 is suppressed in the Xenopus egg extract by CaMKII-catalyzed 
phosphorylation at serine 135.  This prodomain phosphorylation, which is stimulated by 
coenzyme A-induced activation of CaMKII in the extract, is critical in preventing binding of 
caspase-2 to the CARD-containing adaptor protein, RAIDD.  
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In addition to the two phosphorylations characterized by our lab, caspase-2 has 
also been shown to be phosphorylated by protein kinase casein kinase 2 (PKCK2) at 
serine 157 (Shin et al., 2005).  This phosphorylation was, again, shown to be inhibitory 
and could prevent caspase-2 from initiating cell death in response to receptor-induced 
caspase-8 activation (Shin et al., 2005).   
Caspase-2 has also been shown to be post-translationally modified by N-terminal 
acetylation.  This modification promotes activation of caspase-2 by enhancing its binding 
to the pro-apoptotic adaptor protein, RAIDD (Yi et al., 2011).  Interestingly, it has 
recently been suggested that the abundance of acetylation can be regulated by the 
availability of its metabolite cofactor, acetyl-CoA.   These observations, along with the 
metabolically-sensitive phosphorylation discussed above, suggest that caspase-2 could 
function as a critical gauge of cellular fate, coupling apoptotic sensitivity to metabolism 
through dynamic changes in post-translational modifications that influence its 
activation. 
1.2.6 Caspase-2 substrates 
Caspase-2 is unique among other initiator caspases in that it does not directly 
cleave executioner caspases (Guo et al., 2002).  Instead, caspase-2 initiates the apoptotic 
cascade by cleaving the pro-apoptotic BH3-only protein, Bid, which is able to promote 
Bax activation, mitochondrial outer membrane permeabilization, and cytochrome c 
release (Luo et al., 1998).  Mitochondrial release of cytochrome c facilitates the activation 
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of executioner caspases and cell death.  In addition to promoting mitochondrial 
cytochrome c release, caspase-2 propagates the apoptotic pathway through cleavage of 
other substrates which aid in the dismantling of the cell. 
In general, most caspases recognize a four-residue consensus sequence on their 
substrate counterparts.  Interestingly, caspase-2 is the only family member that prefers a 
pentapeptide instead of a tetrapeptide, with VDVAD being its optimal substrate 
sequence (Talanian et al., 1997).  While small peptide-inhibitors based on this consensus 
work well to inhibit caspase-2, they also appear to have some activity toward caspase-3 
and -7 in vivo, suggesting that they lack specificity(McStay et al., 2008).  Because the 
original biochemical studies performed to determine caspase specificity and activity 
relied on the use of synthetic peptide libraries, they are limited in their interpretation 
and cannot be used to unambiguously determine caspase substrates.   
Fortunately, recent findings have utilized high throughput methods based on 
mass spectrometry in order to profile caspase-2 cleavage specificity.  This study, whose 
results have been summarized in Table 1.2, identified close to 40 novel caspase-2 
substrates (Wejda et al., 2012).  Remarkably, many of these substrates shared 
overlapping specificity with executioner caspases, caspase-3 and -7, suggesting that 
caspase-2 could function as a pro-apoptotic caspase once released from it activating 
complex. 
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Table 2.2: Putative caspase-2 substrates and cleavage sites 
Protein name Cleavage site Other caspases 
Eukaryotic translation initiation factor 4B ESDRKD¦GKKD  
Signal recognition particle 54-kDa protein ELDSTD¦GAKV Caspase-3 
Thymosin ß-10 MADKPD¦MGEI  
Actin, cytoplasmic 2 SYELPD¦GQVI  
Prothymosin a DGEEED¦GDED  
Clathrin light chain A GPDAVD¦GVMN Caspase-3 
Myosin-14 LEDTLD¦STNA  
E3 ubiquitin-protein ligase HUWE1 ELLERD¦GGSG  
Filamin-A VVDNAD¦GTQT  
Thimet oligopeptidase AGDMAD¦AASP Caspase-3 
TAR DNA-binding protein 43 KmDETD¦ASSA Caspase-3 
G patch domain & KOW motif-containing protein LPDRQD¦GPAA  
Keratin, type I cytoskeletal 18 LGDALD¦SSNS Caspase-3, -7 
Vimentin LQDSVD¦FSLA Caspase-3, -7 
PRKC apoptosis WT1 regulator protein DEEEPD¦GVPE Caspase-3 
Eukaryotic translation initiation factor 4?1 GEEDAD¦GSKT  
Aspartyl/asparaginyl ß-hydroxylase EQENPD¦SSEP  
Microtubule-associated protein 1B KTDATD¦GKDY Caspase-3, -7 
Prothymosin a EEEEGD¦GEEE  
Zinc finger CCCH domain-containing protein 15 GGDEVD¦DSVS  
Heterogeneous nuclear ribonucleoprotein A0 SPHAVD¦GNTV  
Uncharacterized protein KIAA0174 ETDLID¦VGFT  
Lysyl-tRNA synthetase AEVKVD¦GSEP Caspase-3 
Nucleosome assembly protein 1-like 1 LQERLD¦GLVE  
40 S ribosomal protein S18 QKDVKD¦GKYS  
Endoplasmin EAIQLD¦GLNA  
Myosin-9 LEDTLD¦STAA Caspase-3 
Non-POU octamer-binding protein ATMMPD¦GTLG Caspase-3 
Transcription intermediary factor 1-ß SLDGAD¦STGV Caspase-3 
Acidic leucine-rich nuclear phosphoprotein 32  EEGYND¦GEVD  
Protein HEXIM1 DQEEPD¦LKTG  
Eukaryotic translation initiation factor 4H EFDEVD¦SLKE Caspase-3 
Eukaryotic translation initiation factor 4B DENKVD¦GMNA Caspase-3 
Filamin-A PVDVVD¦NADG  
ATP synthase subunit a, mitochondrial LGNAID¦GKGP Caspase-3 
Pyruvate kinase isozymes M1/M2 ANAVLD¦GADC  
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In addition to the novel substrates listed in Table 1.2, caspase-2 has also been 
shown to cleave and inactivate a number of proteins which contribute to the structural 
disassembly of the cell.  These include structural proteins, Golgin 160, II-spectrin, and 
plakin, as well as proteins which contribute to the maintenance of genomic stability, 
such as ICAD, PARP, and histone deacetylase 4 (HDAC4) (Aho, 2004; Gu et al., 2008; 
Mancini et al., 2000; Paroni et al., 2004; Rotter et al., 2004; Sakahira et al., 1998).  Cleavage 
of these substrates will help facilitate many of the morphological features of apoptosis 
often observed in dying cells, including loss of cellular attachment, cellular rounding 
and DNA fragmentation.   
Interestingly, caspase-2 has recently been suggested to promote apoptotic 
cellular disassembly through the disruption of the cytoskeleton (Vakifahmetoglu-
Norberg et al., 2013).  Unexpectedly, caspase-2 mediated cytoskeletal breakdown was 
shown to be mediated by proteasomal degradation of four proteins including, 
tropomyosin, profilin, stathmin-1 and myotrophin in the setting of DNA damage, 
cytoskeleton disruption and ER stress.  Degradation of these cytoskeleton proteins was 
blunted by siRNA targeting of caspase-2 and none of these proteins was directly cleaved 
by the protease (Vakifahmetoglu-Norberg et al., 2013).  This study demonstrates a novel 
role for caspase-2, being the first to link this protease to proteasomal degradation.  It will 
be interesting to see whether caspase-2 plays a role in promoting the degradation of 
other proteins, beyond just cytoskeletal targets, during apoptosis.    
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1.2.7 Studying apoptosis in Xenopus laevis cell-free egg extract 
Eggs from the African clawed frog, Xenopus laevis, are poised to undergo 
multiple rounds of cellular division following fertilization.  Xenopus eggs are densely 
packed with cellular components and can divide sequentially in the absence of any 
transcriptional input until they reach the 4,000-cell stage.  Xenopus eggs are arrested at 
metaphase II of meiosis with high Cdc2/Cyclin B activity.  By crushing these eggs via 
centrifugation, internal stores of calcium are released, mimicking fertilization and 
leading to the degradation of Cyclin B and exit from mitosis.  The resulting cell-free 
extract can perform protein biosynthesis, allowing Cyclin B to be re-synthesized in the 
ensuing interphase to promote re-entry into mitosis (Murray, 1991).  The degradation 
and re-synthesis of cyclin B will repeat itself, creating an extract that “cycles” between 
interphase and mitosis.  These “cycling” extracts are ideal for examining biochemical 
modifications, changes in binding partners, and alterations in protein levels throughout 
the cell cycle.   
The addition of cycloheximide to the eggs, prior to centrifugation, prevents the 
re-synthesis of cyclin B and results in an extract that is stably arrested in interphase 
(Smythe and Newport, 1991).  Interphase egg extracts can be utilized as a cell-free model 
system to study signaling pathways, as they are capable of recapitulating DNA 
replication , entry into mitosis, and movement through the nuclear pore complex (Blow 
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and Laskey, 1986; Kluck et al., 1997; Murray and Kirschner, 1989; Newport and Forbes, 
1987).  
Initially characterized in 1994 by Newmeyer and colleagues, it was noted that the 
prolonged incubation of Xenopus egg extracts at room temperature resulted in the 
spontaneous activation of apoptosis (Newmeyer et al., 1994).  Subsequent studies further 
demonstrated that this system executes many of the key biochemical events that define 
apoptosis, including mitochondrial cytochrome c release, nuclear fragmentation, and 
caspase activation (Kluck et al., 1997; von Ahsen and Newmeyer, 2000).  Many years 
later, our lab has put forth effort to understand why Xenopus egg extracts undergo 
apoptosis.  Although this thesis suggests more complexity, previous studies by our 
laboratory have suggested the initiating event to be metabolic stress; specifically 
depletion of the pentose phosphate pathway byproduct, nicotinamide adenine 
dinucleotide phosphate (NADPH).  Caspase-2 functions as the initiator caspase in this 
system and it was demonstrated by our lab to be necessary for activation of the 
apoptotic cascade (Nutt et al., 2005).   
In recent years, the Xenopus egg extract system has become a powerful research 
tool for studying the biochemical signaling events of apoptosis.  This is primarily due to 
the ease of manipulation, as the extract lacks a plasma membrane and is therefore, not 
constrained by cell permeability.  Recombinant proteins, pharmacological inhibitors, 
and metabolites can all be easily added to the extract, making it an ideal model for 
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biochemical manipulation.  The influence of such manipulations on apoptotic signaling 
can be easily monitored by assessing caspase activation through the use of colorimetric 
assays or western blotting.  Most importantly, apoptotic signaling pathways are well-
conserved and our laboratory has repeatedly demonstrated the utility of the Xenopus egg 
extract as a model system by confirming many of our findings in mammalian cells.  
1.3 Metabolism  
The complex signaling pathways that control cellular fate can be intimately 
influenced by cellular metabolic status.  Although the ability of nutrients to influence 
intracellular decisions has been appreciated for some time, the complex signaling 
mechanisms linking metabolic inputs to cell proliferation and death are not fully 
understood.  Recently, our lab has demonstrated that caspase-2 is a metabolically-
sensitive enzyme, undergoing dynamic changes in post-translational modification in 
response to alterations in metabolic activity.  Metabolic changes in post-translational 
modifications appear to sensitize caspase-2 to activation and therefore, suggest that 
caspase-2 could function as a critical gauge of cellular fate, coupling apoptotic sensitivity 
to cellular nutrient status.  Understanding the connection between caspase-2 and 
metabolism is the principal goal of this dissertation and thus, a short overview of 
metabolic pathways has been included in this section.  Please note that the specific 
details of these pathways have been summarized and adapted from Biochemistry by Berg 
et al., (2002).  
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1.3.1 Cellular metabolism 
Cellular metabolism refers to the set of intracellular reactions that (1) provide the 
cell with energy from the breakdown of environmental fuel sources and (2) synthesize 
the macromolecules necessary for growth, survival, and proliferation.  Processes which 
breakdown extracellular fuel sources are known as catabolic metabolism and include 
glycolysis, the tricarboxylic acid (TCA) cycle, and fatty acid oxidation (beta-oxidation).  
These pathways, which supply the cell with reducing equivalents in the form of NADH 
and FADH2, fuel the production of cellular ATP.  Processes which synthesize molecules 
necessary for cell growth and survival are known as anabolic metabolism.  The major 
anabolic pathway relevant to this thesis work is fatty acid synthesis, which utilizes 
acetyl-CoA and NADPH to manufacture long-chain fatty acids.  For a summary of these 
major metabolic pathways, see Figure 1.6.   
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Figure 6.6: Cellular metabolic pathways 
 
Figure 1.6: Glucose enters the cell through specialized membrane transporters, called Gluts, 
and is phosphorylated to glucose 6-phosphate (G6P) to prevent its re-exit.  Once 
phosphorylated, G6P can either be used in the pentose phosphate pathway (PPP) to form 
ribose 5-phosphate and produce NADPH or is can enter glycolysis for the production of ATP 
and reducing equivalents. In the glycolytic pathway, G6P is converted into 2 molecules of 
pyruvate (pyr) through a series of reactions that form ATP and NADH.  Pyr can then be 
shuttled into the mitochondrial matrix, where it is converted into acetyl-CoA for oxidation in 
the tricarboxylic cycle (TCA cycle), or under anaerobic conditions, pyr can be converted to 
lactate to regenerate NAD+ for glycolysis. In the TCA cycle, acetyl-CoA and oxaloacetate 
(OAA) condense to from citrate, which then undergoes a series of reactions that produce 
NADH, FADH2 and GTP, eventually reforming OAA for subsequent cycles.  The β−oxidation 
of fatty acids also occurs in the mitochondrial matrix, producing acetyl-CoA (for use in TCA 
cycle) and NADH.  The NADH and FADH2 produced by these reactions are used in oxidative 
phosphorylation to produce ATP, or energy, for the cell.  Citrate, which is formed when 
acetyl-CoA condenses with OAA, can also be exported out of the mitochondria, converted to 
acetyl-CoA, and used in the production of palmitate through the NADPH-dependent 
reactions of fatty acid synthesis.  Adapted from Lindblom and Kornbluth (2014). 
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1.3.2 Glucose metabolism 
Glucose is the most important simple sugar in human metabolism, supplying the 
cell with both energy and reducing power.  Glucose enters the cell through glucose 
transporters, which undergo a conformational change following glucose binding.  Once 
cytosolic, glucose is prevented from exiting the cell via its phosphorylation by the 
enzyme hexokinase, forming glucose-6-phophate (G6P) (Note: this is the first step in 
glycolysis).  G6P can either continue down the glycolytic pathway onto the tricarboxylic 
acid (TCA) cycle, which supports the mitochondrial production of ATP via oxidative 
phosphorylation, or it can be shunted into the pentose phosphate pathway (PPP) to 
produce NADPH through a series of oxidative reactions.  While glycolysis is critical for 
maintaining cellular respiration and ATP production, NADPH is used in the reductive 
biosynthesis of lipids and helps to neutralize toxic reactive oxygen species (ROS) in the 
cell.  Thus, glucose can be utilized in a number of catabolic pathways important for both 
cell growth and defense against damage.  Metabolic flux of glucose may very well be 
dictated by the specific needs of the cell.   
1.3.2.1 Glycolysis 
Glycolysis is a series of ten cytosolic reactions that convert glucose into two 
molecules of pyruvate, with a net gain of two molecules of ATP.  In order for glycolysis 
to occur, NAD+ must be present to act as an electron acceptor in the oxidation of 
glyceraldehyde 3-phosphate, which is the sixth step in the glycolytic breakdown 
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process.  The NADH formed in this reaction can, under aerobic conditions, be re-
oxidized into NAD+ by transferring its electrons to O2 as part of the electron transport 
chain.  Alternatively, under anaerobic conditions, NAD+ can be regenerated through the 
reduction of pyruvate to lactate in an enzymatic process that is catalyzed by lactate 
dehydrogenase.   
1.3.2.2 The tricarboxylic acid cycle 
In order to generate more energy from glucose, the pyruvate produced in 
glycolysis is further broken down in the mitochondria through a series of nine reactions, 
known as the tricarboxylic acid cycle or TCA cycle.  Prior to entering the TCA cycle, 
pyruvate is converted to acetyl-CoA in the mitochondrial matrix by pyruvate 
dehydrogenase.  Acetyl-CoA then undergoes a condensation reaction with oxaloacetate 
to form citrate, a reaction catalyzed by citrate synthase.  Citrate then undergoes a series 
of isomerizations, oxidative decarboxylations, and hydration reactions to eventually 
regenerate oxaloacetate.  Oxaloacetate can then re-combine with another acetyl-CoA 
molecule and repeat the process.   
For every molecule of acetyl-CoA that enters the cycle, two molecules of CO2 will 
be produced.  Additionally, 3 molecules of NAD+ will be reduced to NADH, 1 molecule 
of FAD will be reduced to FADH2, and one molecule of GDP will be phosphorylated to 
GTP.  The reduced electron carriers generated by this process will be oxidized by the 
electron transport chain to produce an additional nine molecules of ATP.  Oxidation of 
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these electron carriers is necessary to regenerate electron acceptors for use in subsequent 
TCA cycles and consequently, restricts function of this cycle to aerobic conditions when 
electrons can be transferred to O2 as part of the electron transport chain. 
1.3.2.3 Oxidative phosphorylation 
The major source of ATP in aerobic organisms is formed through the reactions of 
the electron transport chain, which is also referred to as oxidative phosphorylation.  
These reactions, which utilize the NADH and FADH2 formed in glycolysis, TCA cycle, 
and fatty acid oxidation (discussed in section 1.3.3.2), transfer electrons from these 
donors to molecular oxygen in a series of reactions that form a proton motive force and 
result in the pumping of protons from the mitochondrial matrix into the intermembrane 
space.  ATP is generated when protons flow back into the matrix through the ATP 
synthase enzyme complex. 
The respiratory chain transfers electrons through a series of three proton pumps 
and two mobile electron carriers.  The three main proton pumps consist of large 
transmembrane protein complexes and are named NADH-Q reductase (Complex I), 
cytochrome reductase (Complex III), and cytochrome oxidase (Complex IV).  These 
complexes pump protons across the inner mitochondrial membrane while transferring 
electrons from NADH to the final electron acceptor,O2.  Electrons from NADH are first 
transferred to Complex I and then moved to Complex III by the electron acceptor, 
ubiquinone.  Cytochrome c then shuttles electrons from Complex III to Complex IV, and 
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Complex IV catalyzes their transfer to molecular oxygen to form water.  The process of 
electron transport is similar for electrons donated from FADH2, only this donor first 
transfers its electrons to succinate dehydrogenase (Complex II) before ubiquinone picks 
them up and transfers them to Complex III.  Importantly, succinate dehydrogenase also 
catalyzes the conversion of succinate to fumarate as part of the TCA cycle.  Succinate 
dehydrogenase is the only enzyme that participates in both the TCA and the electron 
transport chain and serves to link the glycolytic flux between these two metabolic 
processes.    
The proton gradient created by the transport of electrons across the respiratory 
complexes is utilized by the ATP synthase enzyme to catalyze the phosphorylation of 
ADP to ATP.  The oxidation of NADH and FADH2 is tightly regulated by the level of 
ATP, such that when the ATP levels are high, electron transport is halted since 
additional energy production is not needed. 
1.3.3 Lipid metabolism 
Lipid metabolism is a complex process that involves several different pathways 
that interdependently regulate the breakdown and synthesis of fats.  For the purposes of 
this dissertation, the discussion will focus on fatty acids, the most commonly stored and 
circulating forms of lipid energy.  Fatty acids are carboxylic acids with long hydrocarbon 
chains that can be either saturated (without double bonds) or unsaturated (containing 
one or more carbon-carbon double bonds).  Fatty acids can exist as uncombined fatty 
  
40 
acids, known more commonly as free fatty acids, which circulate in the blood while 
bound to serum albumin.  Fatty acids can also exist as triglycerides or phospholipids.  
These more inert forms of fatty acids can facilitate the transport of lipids from adipose 
tissues to other areas of the body as well as serve as a major component of cellular 
membranes.  Fatty acids, both free and glycerol-bound (triglycerides), can originate from 
four major sources: de novo fatty acid synthesis, cytoplasmic triglyceride stores, 
circulating lipoproteins, and circulating free fatty acids.   
Due to their water insolubility, free fatty acids are transported in the blood in a 
complex with the protein serum albumin.  Once taken up by a cell, fatty acids have 
several fates: (1) They can enter the mitochondria (in a reaction that requires carnitine) 
and be used for energy production (through the TCA cycle) via beta-oxidation or (2) 
they can recombine with glycerol to form triglycerides for storage purposes or in the 
case of the liver, get packaged into very-low-density-lipoprotein (VLDL) through 
condensation with cholesterol and apolipoprotein for export into the blood.  The uptake 
of triglycerides usually results in the release of free fatty acids and a glycerol molecule.  
While free fatty acids are processes as above, glycerol is usually taken up by the cell and 
used for glucose production or recycled for triglyceride formation.    
Healthy individuals contain very low concentrations of free fatty acids in the 
blood.  An increase in circulating free fatty acids typically occurs when: (1) the body is 
breaking down fat, which occurs when the glucose supply is unable to meet energy 
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demands or (2) during periods of over-nutrition, when free fatty acids accumulate to 
levels that exceed the storage capacity of adipose tissue.  Such an imbalance between 
energy demand and food supply can be detrimental, predisposing animals to liver 
steatosis (excessive fatty acid storage within the hepatocyte).  The negative consequences 
of liver steatosis will be discussed in greater detail in section 1.4. 
1.3.3.1 Fatty acid synthesis 
Fatty acids are synthesized in the cytoplasm by a large enzyme complex known 
as fatty acid synthase (FASN).  This complex performs a four-step energy-consuming 
reaction that results in the elongation of a carbon chain by 2 carbon units every cycle.  It 
uses acetyl-CoA as a substrate and through the consumption of ATP and CO2, first 
activates this molecule to malonyl-CoA, a 3-carbon compound.  Malonyl-CoA is then 
added to the growing carbon chain through a series of reduction reactions which 
consume NADPH and elongate the growing chain by 2 carbon units.  The final product 
of fatty acid synthesis is palmitate, a 16-carbon chain saturated fatty acid.  Modification 
of palmitate leads to other shorter and longer chain fatty acids, while desaturation of the 
carbon chain is performed by specific enzymes, known as fatty acid CoA desaturases.  
Fatty acid synthesis is required for the production of fatty acids used in phospholipid 
biosynthesis and it functions to store excess cellular energy in the form of fat.   
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1.3.3.2 Beta-oxidation 
When it is necessary to utilize fats as energy, beta-oxidation of fatty acids takes 
place in the mitochondrial matrix.  In order to enter the matrix, cytosolic fatty acids must 
first be activated through a thioester linkage to CoA, which is catalyzed by acyl CoA 
synthetase and occurs on the outer mitochondrial membrane.  Next, fatty acid CoAs are 
conjugated to carnitine to form acylcarnitines, which can be shuttled across the inner 
mitochondrial membrane into the matrix.  Once in the matrix, carnitine is removed and 
the acyl CoA is degraded through a series of four reactions: oxidation by flavin adenine 
nucleotide (FAD), hydration, oxidation by NAD+, and thiolysis by CoA.  Each round of 
reactions will reduce the acyl CoA chain by two carbon units, producing acetyl-CoA , 
NADH, and FADH2.  The reduced electron carriers generated by this process help fuel 
energy production via oxidative phosphorylation (section 1.3.2.3), while the acetyl-CoA 
molecule can be further utilized in the TCA cycle for energy generation (see section 
1.3.2.2).   
1.4 Obesity and apoptosis 
During periods of overnutrition, long-chain fatty acids (LCFAs) accumulate and 
saturate the storage capacity of adipose tissue.  As a result, LCFA levels become elevated 
in the plasma, resulting in increased import and storage of these molecules in non-
adipose tissues (Frayn, 2002; Kusminski et al., 2009; Lewis et al., 2002).  The over-
accumulation of lipids in non-adipose tissues can result in chronic cellular dysfunction 
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and programmed cell-death.  These processes, which are now commonly referred to as 
lipotoxicity and lipoapoptosis, have profound impact on tissue function and appear to 
be a critical part of the etiology of diseases associated with metabolic syndrome 
(Cazanave and Gores, 2010; Kusminski et al., 2009; Listenberger and Schaffer, 2002; 
Unger et al., 2010).   
1.4.1 Lipotoxicity and lipoapoptosis 
In normal cellular settings, the uptake and production of lipids is carefully 
balanced with their oxidation and transport.  Overnutrition, inactivity, and environment 
are all factors that can increase the amount of free fatty acids circulating in the blood, 
resulting in an increased uptake of these molecules without a corresponding increase in 
their oxidation.  This type of metabolic imbalance will lead to an over-accumulation of 
free fatty acids within the cell and without proper neutralization of these lipids, can 
result in chronic cellular dysfunction (Schaffer, 2003).   
Upon entering a cell, fatty acids can be converted into different types of lipids for 
storage, most often being converted into triglycerides, which are considered the most 
neutral and harmless of intracellular lipids.  Triglycerides are stored as cytoplasmic lipid 
droplets and while adipose cells have a unique capacity to store large amounts of lipids, 
non-adipose cells do not.  Thus, an excess accumulation of lipid droplets in non-adipose 
cells will result in dysfunction, which in the case of the pancreas means diminished 
insulin secretion and in the case of the liver means impaired insulin-stimulated glucose 
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transport (Schaffer, 2003).  The detrimental effects of lipid accumulation depend on the 
cell type and the degree of lipid overload.  Prolonged exposure to high amounts of lipids 
can trigger apoptotic cell death, a process which is now commonly referred to as 
lipoapoptosis.   
Lipoapoptosis has been shown to affect many cell types, including hepatocytes in 
the liver, cardiomyocytes in the heart, and islet beta cells in the pancreas.  These cells, 
which specifically undergo apoptosis in response to treatment with saturated fatty acids, 
display several characteristic features of the intrinsic apoptotic pathway, including 
mitochondrial permeabilization, cytochrome c release, and effector caspase activation.  
While the role of the mitochondria and cytochrome c release has been well-established in 
LCFA-induced lipoapoptosis, the core apoptotic machinery engaged by toxic 
concentrations of LCFA upstream of the mitochondria has not yet been reported and 
will be discussed in this dissertation. 
Understanding how lipids induce cell death is important for managing diseases 
that are exacerbated by lipid-induced cytotoxicity.  Thus, multiple studies have focused 
on identifying the specific lipid species that triggers apoptosis.  Data demonstrating that 
a non-metabolizable fatty acid (2-bromoplamitate) induces apoptosis in islet beta cells 
suggests that free fatty acids may be the toxic offenders (Cnop et al., 2001) .  Moreover, 
there have been several studies showing the toxic effects of saturated but not 
unsaturated fatty acids, suggesting that saturated fatty acids may be central to apoptotic 
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induction (de Vries et al., 1997; Furstova et al., 2008; Hardy et al., 2003; Kim et al., 2008; 
Mei et al., 2011; Staiger et al., 2006).  For example, saturated fatty acids serve as a 
precursor molecule for the de novo synthesis of ceramide, a lipid signaling molecule that 
is known to induce apoptosis.  While ceramide synthesis can be increased following the 
treatment of cells with LCFAs, ceramide only induces apoptosis in some cell types and 
thus, may not be the critical effector triggering lipoapoptosis (de Vries et al., 1997; 
Listenberger et al., 2001).  In addition to ceramide production, free fatty acids may 
induce lipoapoptosis through the production of ROS either by increased production of 
nitric oxide or reactive oxygen radicals coming from oxidative phosphorylation (Kong 
and Rabkin, 2002; Piro et al., 2002; Shimabukuro et al., 1997).   
1.4.2 Lipoapoptosis as a critical mediator of nonalcoholic fatty liver 
disease 
Lipoapoptosis has recently gained recognition as a critical mediator of 
nonalcohlic fatty liver disease (NAFLD).  NALFD is a progressive liver disease in which 
excessive fatty acid uptake by the liver results in hepatocyte cell death (Neuschwander-
Tetri, 2010).  Hepatocellular lipoapoptosis has been demonstrated to be a critical 
mechanism driving the progression of NAFLD to the more advanced stage of the 
disease, nonalcoholic steatphepatitis (NASH).  NASH is characterized by an increase in 
liver cell injury as well as cell death (Feldstein et al., 2003) .  NASH can result in an 
irreversible scarring of the liver, which is known as cirrhosis, and upon prolonged 
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stress, can cause liver failure.  Currently, NASH-related cirrhosis is the third leading 
cause of liver transplantation in the United States (Charlton et al., 2011).   
NAFLD affects 25% of the population here in the United States, although many 
believe this to be an underestimation, as patients usually have little to no symptoms 
often only complaining of fatigue or mild abdominal discomfort.  NAFLD is typically 
diagnosed by abnormal liver enzyme levels during routine blood tests, which may 
indicate that there is a decrease in liver function.  Mild to moderate elevations of the 
serum aminotransferases (aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT)) are most commonly found but serum alkaline phosphatase and 
g-glutamyl transpeptidase levels can also be abnormal.  A liver biopsy is then usually 
performed to differentiate NAFLD from NASH.  If the tissue shows lipid deposits 
without inflammation or cellular damage, NAFLD is diagnosed.  However, if the tissue 
shows infiltration of inflammatory cells, damage to hepatocytes and liver scarring, 
NASH is noted.  Once patients have progressed to this state, there is little that can be 
done to reverse liver damage.  Therefore, it is important to find a therapeutic entry point 
for halting the progression of NAFLD.   
Lipoapoptosis has been shown to be a critical mediator of liver scarring, fueling 
the production of type I collagen in a process known as fibrogenesis (Figure 1.7).  More 
specifically, hepatocyte apoptosis promotes the activation of a group of cells in the liver 
known as hepatic stellate cells (HSCs).  These cells, which activate upon the engulfment 
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of apoptotic bodies, begin secreting type I collagen (collagen 1α1) (Canbay et al., 2003).  
Collagen secretion results in fibrosis or cirrhosis and correlates with negative patient 
outcomes (Malhi et al., 2010).  Since lipoapoptosis is a critical mediator of fibrosis in 
NASH, it is important to understand the apoptotic signaling events regulating cell death 
in order to find a potential therapeutic target.  In Chapters 5 of this dissertation, we 
evaluate the hypothesis that lipoapoptosis of hepatocytes is mediated by the activation 
of caspase-2, thereby driving the progression and pathogenesis of NASH-related 
cirrhosis.   
 
Figure 7.7: Progression of NAFLD 
 
Figure 1.7: An increased level of free fatty acids in the serum promotes the uptake and 
deposit of excess fatty acids in the liver, resulting in steatosis.  Steatosis triggers cellular 
dysfuction, or lipotoxicity, resulting in the nonalchoholic fatty liver disease (NAFLD).  
Prolonged exposure to excess fatty acids will trigger apoptotsis of hepatocytes, resulting in the 
activation of hepatic stellate cells (HSCs).  Following activation, HSCs secrete collagen to 
promote liver fibrosis and cirrhosis.  Fibrosis is indicative of the more advanced stage of liver 
disease, known as nonalchoholic steatohepatitis, or NASH. 
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2. Materials and Methods 
2.1 Xenopus techniques 
2.1.1 Xenopus egg extract 
Mature Xenopus laevis female frogs were induced to lay eggs by injection of 
exogenous -human chorionic gonadotropin (-HCG) hormone as described previously 
(Smythe and Newport, 1991).  24h post-injection, eggs were collected and jelly coats 
were removed from the eggs with 2% cysteine (pH 8.0).  Eggs were washed three times 
with modified Ringer's solution (MMR: 1 M NaCl, 20 mM KCl, 10 mM MgSO4, 25 mM 
CaCl2, 5 mM Hepes, pH 7.8, 0.8 mM EDTA) and then three times with egg lysis buffer 
(ELB: 250 mM sucrose, 2.5 mM MgCl2, 1.0 mM dithiothreitol, 50 mM KCl, 10 mM Hepes, 
pH 7.7).  Eggs were centrifuged at 400 g, excess buffer was removed, and cytochalasin B 
(5 µg/mL; Calbiochem), aprotinin/leupeptin (5 µg/mL), and cyclohexamide (50 µg/mL) 
were added.  Egg lysis was performed by centrifugation at 10,000 g for 12 minutes.  
Crude cytosolic egg extracts were collected using a syringe and stored on ice until time 
of use.  Prior to use, egg extract was supplemented with an energy regenerating mix (2 
mM ATP, 50 μg/mL creatine kinase, and 20 mM phosphocreatine).  
2.1.2 Caspase Assay 
Xenopus egg extract caspase assays were performed using crude cytosolic extract, 
as described previously by our lab (Deming et al., 2004).  Caspase-3 activity was 
measured spectrophotometrically by assessing the cleavage of the colorimetric substrate 
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Ac-DEVD-pNA.  Briefly, 5 µL of crude cytosolic egg extract was removed and incubated 
in 85 µL of DEVDase buffer (50 mM Hepes (pH 7.5), 100 mM NaCl, 0.1% CHAPS, 10 mM 
DTT, 1 mM EDTA, 10% glycerol) and kept on ice.  Following collection of all samples, 10 
μl of the colorimetric peptide substrate, Ac-DEVD-pNA (200 mM final concentration; 
BIOMOL Research Labs, INC.), was added to each sample and incubated at 37°C for 30–
60 minutes.  Absorbance of the colorimetric product was measured at 405 nm using a 
Bio-Rad microplate reader (Bio-Rad Microplate Reader, Model 680).  Absorbance data 
was analyzed using data-plotting software. 
Caspase-2 activity assays were performed according to the BioVision caspase-2 
colorimetric assay kit specifications (BioVision).  Briefly, 10 μL of crude cytosolic egg 
extract was removed and incubated in 40 μL cell lysis buffer.  All samples were diluted 
with 50 μL of 2X reaction buffer and then incubated with 10 μL of VDVAD-pNA (4mM 
final concentration) at 37°C for 60–120 minutes.  Absorbance of the colorimetric product 
was measured at 405 nm using a Bio-Rad microplate reader and the absorbance data 
was analyzed using data-plotting software. 
2.1.3 In vitro translated caspase-2 protein synthesis 
35S-labeled, in vitro translated, full-length caspase-2 proteins were synthesized 
using the TNT SP6 quick-coupled transcription/translation system (Promega).  Briefly, 
20 ng/μl of pSP64T Xenopus caspase-2 cDNA was added to rabbit reticulocyte lysate 
containing 0.4 mCi/mL 35S-Translabel, 1x (minus-cysteine, minus-methionine) amino 
  
50 
acid mixture, and additional components in accordance with the manufacturer’s 
protocol.  The reactions were incubated at 30C for one hour and then stored at -80C 
until needed. 
2.1.4 Analysis of in vitro translated caspase-2 protein processing 
35S-labeled, in vitro translated, full-length caspase-2 proteins were added to the 
extract at a 1:10 ratio.  Samples of extract containing radiolabelled caspase-2 were 
removed over time, denatured by SDS sample buffer, resolved on SDS-PAGE.  
Proenzyme processing was assayed by autoradiography using a phosphorimager 
(Molecular Dynamics). 
2.1.5 Fatty acid preparation and supplementation 
20 mM fatty acid stock solutions were made by complexing sodium palmitate to 
10% fatty-acid free bovine serum albumin (BSA).  For palmitate, 74.24 mg of sodium 
palmitate (Sigma #P9767) was dissolved in 4 mL of water in a small glass beaker.  The 
solution was heated on a hot plate, stirring constantly until the solution went clear.  A 
cold mixture of 13.3 mL of 30% fatty acid free BSA (Sigma A-9205) and 20 mL of water 
was added to the fatty acid solution and brought to a final volume of 40 mL.  The 20 mM 
stock solution was then filtered sterilized through a 0.45 μm filter, followed by filtration 
through a 0.20 μm filter.  A control BSA stock solution was made by adding BSA to 
water only, followed by filtration as described above.  Stock solutions were aliquoted 
and frozen at -20°C for later use.  To test the effects of exogenous fatty acid 
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supplementation on extract apoptosis, BSA or BSA-conjugated palmitate was added to a 
final concentration of 4 mM after extract preparation.  Extracts were then warmed to 
room temperature and caspase assays were performed.  
2.1.6 NAD+/NADH nucleotide analysis 
NAD+ and NADH levels were measured using the NAD+/NADH quantitation 
kit (BioVision).  Briefly, extract samples were removed at the indicated time points a 
diluted 1:40 in NAD+/NADH extraction buffer.  Samples were vortexed, spun through a 
10kDa molecular weight cutoff filter, and then divided evenly.  Half the sample was 
used for the measurement of total NAD+ and NADH (NADt) and the other half was 
used to measure NADH following decomposition of NAD+ by incubating at 60°C for 30 
minutes.  All samples were added to a 96-well plate and the cycling reaction was 
performed at room temperature for 2 hours.  Absorbance of the colorimetric product was 
measured at 450 nm using a Bio-Rad microplate reader and the absorbance data was 
analyzed using data-plotting software. 
2.1.7 Oxygen consumption analysis 
Oxygen (O2) consumption rates were measured using the Seahorse extracellular 
flux XF24 analyzer (Seahorse Biosciences).  Briefly, freshly prepared egg extracts were 
added in triplicate to a 24-well plate and analyzed for 4 h.  O2 consumption rates were 
measured every 10 minutes and analyzed using the “(Level) Direct (Ksv)” method and 
data-plotting software. 
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2.2 Metabolomic profiling (performed in collaboration with Dr. 
Chris Newgard) 
2.2.1 Sample preparation 
Metabolic profiling was performed on both freshly prepared Xenopus egg 
extracts (fresh) and extracts incubated at room temperature for 3-4 h, but harvested prior 
to caspase activation (aged).  300 μL of extract was removed from fresh and aged 
samples followed by protein precipitation with either methanol (1200 μL) or acidified 
acetonitrile (750 μL ACN + 450 μL 1% formic acid).  Samples were mixed well by vortex, 
spun down, and supernatants were removed immediately and stored at -80C until 
sample analysis. 
2.2.2 Amino acid and acylcarnitine analysis  
Measurements of amino acid (AA) and acylcarnitine (AC) were made by flow-
injection electrospray tandem mass spectrometry of their butyl and methyl esters, as 
described previously (An et al., 2004; Wu et al., 2004).  Briefly, supernatants were 
supplemented with a mixture of internal standards and then evaporated under nitrogen 
using a SPE Dry-96 Jones chromatography apparatus.  Residues were incubated with 3M 
MeOH-HCl (Supelco Inc.) or 3M BuOH-HCl (Regis Chemical Company), depending on 
whether methyl ester or butyl ester derivatives of the samples were to be prepared, 
followed by evaporation of the reagent under nitrogen.  200 μL methanol:water (85:15, 
v/v) was added to each sample and AA and AC analytes were measured by direct 
injection electrospray tandem mass spectrometry, using a Waters AcquityTM  UPLC 
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system equipped with a TQ (triple quadrupole) detector and a data system controlled by 
MassLynx 4.1 operating system (Waters).  AA were detected by positive neutral loss 
scans of 102, 119, and 161 Da, and AC profiles were generated using a precursor scan 
function (m/z 99 for methylesters or m/z 85 for butyl esters).  The ratios of molecular 
signals to their respective internal standards were used to quantify the analytes.  For 
several analytes, the lack of available analytical standards required reporting a 
dimensionless value based on the analyte to internal standard ratio. 
2.2.3 Organic acid analysis 
Organic acid (OA) analytes were extracted into ethyl acetate, dried and then 
converted to trimethyl silyl esters by N,O-bis (trimethylsilyl) trifluoroacetamide, with 
protection of α-keto groups by oximation with ethoxyamine hydrochloride.  OA were 
analyzed by capillary gas chromatography/mass spectrometry (GC/MS) using a TRACE 
DSQ instrument (Thermo Electron Corporation).  All MS analyses employed stable-
isotope dilution with internal standards from Isotec (St. Louis, MO), Cambridge Isotope 
Laboratories (Andover, MA), and CDN Isotopes (Pointe-Claire, Quebec, Canada).   
2.3 Mammalian cell techniques  
2.3.1 Cell culture 
Hek 293T, HeLa, HepG2, and AML12 cell lines were obtained from the American 
Type Culture Collection (ATCC).  Hek 293T, HeLa, and HepG2cells were grown in high-
glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
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bovine serum (FBS).  AML12 cells were maintained according to the specifications of the 
ATCC in a 1:1 mixture of DMEM and Ham's F12 medium with 0.005 mg/ml insulin, 
0.005 mg/ml transferrin, 5 ng/ml selenium, and 40 ng/ml dexamethasone and 
supplemented with 10% FBS.  Hek 293T and HeLa cells were passaged via incubation in 
0.05% Trypsin-EDTA, while HepG2 and AML12 cells were passaged via incubation in 
0.25% Trypsin-EDTA.  All cultures were maintained at 37C with 5% CO2. 
2.3.2 siRNA transfection 
For siRNA-mediated knockdown of caspase-2 in human cell lines (Hek 293T and 
HepG2), custom caspase-2 oligos targeting to the 3′ untranslated region of caspase-2 
were ordered from Sigma-Aldrich.  The sequence for the caspase-2 siRNA used was 
UGGAAGUAUUUGAGAGAGA[dT] [dT].  For siRNA-mediated knockdown of 
caspase-2 in murine cells (AML12), Smartpool siRNA targeting mouse caspase-2 (catalog 
number M-044184-00) and ON-TARGETplus control siRNA #1 (catalog number D-
001810-01-05) were obtained from Dharmacon.  RNAi reagents were transfected using 
RNAi Max (Invitrogen) following the manufacturer’s protocol and media was changed 
24 h post-transfection.  siRNAs were transfected for 48 to 72 hours and cells were 
collected either by gentle scraping or using trypsinization.   Collected cells were washed 
once in ice-cold PBS, pelleted by centrifugation, and then further processed or snap-
frozen in liquid nitrogen for storage at -80C. 
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2.3.3 Fatty acid preparation and treatments 
In order to avoid the addition of organic solvents to the cell culture medium, 
solutions containing fatty acid sodium salts bound to albumin were prepared from stock 
solutions of the fatty acid sodium salt and media containing fatty acid-free BSA (2%).  
Fatty acid stock solutions were prepared by dissolving the fatty acid sodium salt in 
water at 70°C to a final concentration of 100 mmol/L.  For example, palmitate solutions 
were made by dissolving 28 mg of sodium palmitate in 1 mL sterile H2O and heating at 
70°C until the solution was clear.  This solution was then added to the cell culture media 
containing 2% fatty acid-free BSA and these solutions were used after filtration through 
0.22-μm filters.   
2.3.4 Caspase assay 
Caspase-2 activity assays were performed according to the BioVision caspase-2 
colorimetric assay kit specifications (BioVision).   
2.3.5 Western blot analysis 
For western blot analysis, mammalian cells were lysed in RIPA buffer (50 mM 
Tris Base, 1 mM EDTA, 1% NP-40, 0.25% NaDoC, 0.1% SDS, pH 7.4) with 100 mM PMSF 
and 5 μg/mL aprotinin and leupeptin.  Lysates were centrifuged at 4°C for 15 minutes at 
14,000 g and protein concentration of the supernatant was determined using the BioRad 
protein assay reagent.  50 μg of protein was separated on a 12% SDS PAGE gel and then 
transferred to PVDF membrane at 80 volts for 90 minutes.  Membranes were blocked 
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with 5% non-fat dry milk in TBST (0.25 M Tris Base, 4.5% NaCl, pH 7.4, 0.1% Tween-20) 
for 30 minutes at room temperature and then incubated with primary antibodies (1:1,000 
dilution in TBST) overnight at 4°C.  The next day, membranes were washed 3 x 5 
minutes with TBST and then incubated with infrared fluorescent secondary antibodies 
(1:10,000 dilution in TBST) for 1 hour at room temperature.  Membranes were washed 3 
x 5 minutes with TBST and then analyzed using the Li-Cor Odyssey Infrared Imaging 
System (Lincoln, NE).  Antibodies used were anti-caspase-2 (polyclonal, Abcam 
(ab7979)); anti-caspase-2 (monoclonal, BD Transduction Laboratories (Clone G310-
1248)); and anti-actin (polyclonal, Santa Cruz (I-19)).  Secondary antibodies were 
IRDye® 800CW Goat (polyclonal) anti-mouse from Odyssey and Alexa Fluor ® 680 Goat 
anti-rabbit from Invitrogen. 
2.3.6 Gel filtration chromatography 
293T cells were treated with 2% BSA or 2% BSA + 1 mM palmitate for 18 hours 
before lysis by dounce homogenization in hypotonic lysis buffer (20 mM HEPES pH 7.5, 
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 5 μg/ml each 
aprotonin and leupeptin).  Lysates were centrifuged at 4°C for 15 minutes at 16, 000 g 
and protein concentration of the supernatant was determined using the BioRad protein 
assay reagent. 500 μL of 8 mg/mL lysates were loaded onto a Superdex 200 column at a 
flow rate of 0.3 mL/minute.  Fractions were collected and analyzed by western blotting. 
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2.3.7 Bimolecular fluorescence complementation 
Caspase-2 bimolecular fluorescence complementation (BiFC) expression vectors 
were constructed by standard PCR cloning in a manner similar to the design by the 
Douglas R. Green Lab (Bouchier-Hayes et al., 2009).  Briefly, caspase-2 prodomain 
(amino acids 1-169) was inserted into pBiFC-VN173 (Addgene, 22010) and pBiFC-VC155 
(22011) at the N-termini of the split-venus fragments.  Simultaneously, an N-terminal c-
Myc tag was substituted for the pBiFC-VC155 HA tag.  Flag-caspase-2-VN173 and c-
Myc-caspase-2-VC155 fusions were then inserted into the MCSI and MCSII, respectively, 
of pTRE-Tight-BI (Clontech, 631068) for tetracycline-controlled expression. 
To generate stable cell lines, the pTRE-Tight-BI caspase-2 BiFC construct was 
linearized and then co-transfected into HeLa Tet-Off cells (Clontech, 631156) with 
Clontech’s Linear Hygromycin Marker (631625) at a 5:1 ratio.  After 24 h, transfected 
cells were split to low confluency and then treated with 200ug/mL hygromycin for 2 
weeks to select for clonal populations.  Clones were harvested and then tested for 
protein expression and BiFC response. 
Stable BiFC cells were maintained in DMEM supplemented with 10% FBS, 
100ug/ml geneticin, 100ug/ml hygromycin, and 1ug/ml doxycycline (Dox).  Prior to 
treatment, cells were washed twice with PBS to remove Dox and then switched to 
DMEM supplemented with 10% Tet-System Approved FBS (Clontech) for 24 h to allow 
expression of the caspase-2-BiFC fragments.  Cells were then treated with 1mM 
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palmitate or 2% BSA for 24 h in the presence of 10μM of the pan caspase inhibitor Q-VD-
OPh to prevent executioner caspase activation and cell death.  To detect BiFC, cells were 
analyzed by flow cytometry. 
2.3.8 Propidium ioidide staining 
To assess cellular apoptosis, Hek293T, HepG2, and AML12 cells were analyzed 
for propidium iodide (PI) uptake.  Cells were treated with 2% BSA or 2% BSA + fatty 
acids and then collected via trypsinization.  Samples were washed once with 1X PBS and 
then resuspended in 1 μg/mL PI (dissolved in PBS), and kept on ice until analysis.  
Samples were protected from light and analyzed immediately at the Duke University 
flow cytometry core facility.    
2.4 Mouse model techniques (performed in collaboration with Dr. 
Anna Mae Diehl) 
2.4.1 Murine models 
For caspase-2 expression studies, 5 male wild-type mice, strain C57BL/6, were 
obtained from Jackson Laboratories (Bar Harbor, ME).  Animals were fed a methionine 
choline-deficient (MCD) diet (MP Biomedicals) for 8 weeks.  Equal numbers of mice 
were fed standard rodent food (4.7 kcal/g: 13% calories as fat, 62% as carbohydrates and 
24% as proteins) as a control. 
For diet-induced disease studies, 10 caspase-2 knockout mice, strain B6.129S4-
Casp2tm1Yuan/J (stock no. 007899), and 10 wild-type mice, strain C57BL/6J (stock no. 
000664), were purchased from Jackson Laboratories.  Five animals per group were fed a 
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high fat (HF)/MCD diet or the same HF diet supplemented with methionine and choline 
(MP Biomedicals) for 8 weeks (4.5 kcal/g: 20% calories as fat, 58% as carbohydrates and 
22% as proteins).  
At the end of all treatments, mice were fasted for 6 hours and sacrificed. Livers 
were harvested and either formalin-fixed or snap frozen.  All mice were maintained in a 
temperature- and light-controlled facility.  Animals were age-matched and experiments 
were begun at approximately 8 weeks of age.   
Animal care and procedures were approved by the Duke University Institutional 
Animal Care and fulfilled National Institutes for Health and Duke University IACUC 
requirements for humane animal care. 
2.4.2 Hepatocyte isolation 
Mouse hepatocytes were isolated from 3 caspase-2-/- mice and 3 control mice 
using in situ liver perfusion, collagenase digestion, and differential sedimentation (Berry 
and Phillips, 2000). Viability/purity was assessed by trypan blue exclusion. Hepatocytes 
were seeded onto plastic culture dishes in DMEM/F12 (Invitrogen) supplemented with 
10% FBS, ITS (1:200; Invitrogen), dexamethasone (1 mM; Sigma) and antibiotics (Life 
Technologies). After 24 hours, cells were treated with similar media but supplemented 
with 2% BSA with or without 1 mM palmitate (Sigma #P9767) for 48 h.  
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2.4.3 Histopathological Analysis 
Formalin-fixed, paraffin-embedded liver biopsies were cut into 5 m serial 
sections and for immunohistochemistry, sections were deparafinized with xylene and 
rehydrated.  Slides were incubated in 3% hydrogen peroxide/methanol and antigen 
retrieval was performed by heating in 10 mM sodium citrate (pH 6.0).  Sections were 
blocked (X9090; Dako Envision) and incubated overnight at 4ºC with caspase-2 
antibody, 1:3000 (Santa Cruz Biotechnology, sc-626R). Horseradish peroxidase (HRP)-
conjugated IgG secondary antibody was used and antigens were demonstrated by 
diaminobenzidine (DAB) (Dako Envision, K3466).  Tissue sections were counterstained 
with Aqua Hematoxylin-INNOVEX (Innovex Biosciences).  Morphometric analysis with 
Metamorph Software (Molecular Devices Corporation) was performed for 
quantification. 
2.4.4 TUNEL staining 
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling 
(TUNEL) assay (Boehringer Mannheim, Mannheim, Germany) was performed 
according to the manufacturer’s protocol. 
2.4.5 Fibrosis staining 
To assess liver fibrosis, sections were stained with Picrosirius red (Sigma) and 
counterstained with Weigert’s haematoxylin (Polysciences, Inc).  Quantification was 
done by morphometric analysis with Metamorph Software (Molecular Devices 
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Corporation) in sections that were randomly chosen (under x10 magnification, 20 fields 
each from sample)(Choi et al., 2006).  
2.5 Reagents 
2.5.1 Antibodies 
Anti-caspase-2 (polyclonal, 1:1000) was purchased from Abcam (ab7979); anti-
caspase-2 (monoclonal, 1:1000) from BD Transduction Laboratories (Clone G310-1248); 
and anti-actin (polyclonal, 1:1000) from Santa Cruz (I-19).   
2.5.2 Additional Reagents 
Aminooxyacetate (Sigma-Aldrich) was used at 10 mM.  D-Glucose 6-phosphate 
sodium salt (Sigma-Aldrich) was used at 20 mM.  Triacsin C, etomoxir, and fatty acid 
sodium salts were purchased from Sigma-Aldrich, with the exception of sodium 
palmitoleate, which was purchased from Nu-Chek Prep, Inc.  Bovine Serum Albumin 
(Fraction V, heat shock, fatty acid ultra-free) was purchased from Roche, unless 
otherwise specified. 
2.6 Statistics 
The results represent the means ± S.E. of the mean.  For mammalian cell studies, 
statistical significance was determined using a two-tailed Student’s t test for three 
independent experiments, with significance at p < 0.05.  For murine model experiments, 
significance was established using Student’s test and Spearman correlation, with 
significance at p < 0.05.  
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3. Metabolic stress-induced activation of caspase-2 in 
Xenopus laevis egg extracts 
This chapter appears in modified form in the Journal of Biological Chemistry. 
2013 May 17; 288(20): 14463-75. 
3.1 Introduction 
As discussed in Chapter 1, apoptosis is a form of programmed cell death that is 
activated in response to pro-death stimuli.  Characterized by rapid cellular 
fragmentation and phagocytosis, apoptosis eliminates damaged or unneeded cells, while 
preserving the integrity of the surrounding tissue.  Disruption of the apoptotic program 
can result in inappropriate cell survival, enabling cancer cells to continue propagating 
despite the presence of pro-death signals from hypoxia, chemotherapeutics, and DNA 
damage.  In contrast, too much apoptosis can result in tissue dysfunction and is often a 
hallmark of chronic degenerative disorders.   
Apoptosis is characterized by the activation of a group of cysteine proteases 
known as caspases.  Caspases, which are divided into two classes, initiator or 
executioner, based on their position in the apoptotic hierarchy, dismantle the cell in an 
orderly, energy-dependent manner.  Caspase-2, which is the most evolutionarily 
conserved caspase, functions as an initiator and activates the intrinsic apoptotic cascade.  
The prevailing model is that caspase-2, once activated, cleaves the BH3-only protein Bid 
to generate truncated Bid (tBid), which activates Bax to promote mitochondrial 
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cytochrome c release.  Despite being one of the most conserved caspases, the regulation 
and precise functions of caspase-2 have remained somewhat unclear.   
Physiologically, the role of caspase-2 is not entirely clear.  The only overt 
developmental phenotype in the caspase-2 KO mouse was an overabundance of oocytes, 
suggesting a central role for caspase-2 in controlling oocyte cell death (Bergeron et al., 
1998).  Extending our understanding of the role of caspase-2 in oocytes, our laboratory 
has used Xenopus laevis oocytes and eggs to study the metabolic regulation and 
activation of caspase-2.   Previously, our lab demonstrated that incubation of Xenopus 
egg extract at room temperature leads to activation of the apoptotic cascade via caspase-
2 and that caspase-2 is required to execute apoptosis in this system (Nutt et al., 2005).  
Moreover, it was discovered that caspase-2 activation occurred only after specific 
metabolic changes (e.g., depletion of NADPH) and was regulated through suppressive 
binding of the small, acidic protein 14-3-3ζ (Nutt et al., 2009).  Release of 14-3-3ζ, and 
thus activation of caspase-2, could be blocked by supplementing the extract with 
metabolites leading to NADPH production, either through malic enzyme or the pentose 
phosphate pathway (Nutt et al., 2009; Nutt et al., 2005).  Based in part on these 
observations, it was hypothesized that the activation of caspase-2 in this system was 
regulated by cellular metabolic status, whereby extract incubation results in nutrient 
starvation, loss of 14-3-3ζ binding, and activation of caspase-2.   
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Recently, our lab demonstrated that the removal of 14-3-3ζ from caspase-2 is 
regulated via changes in 14-3-3ζ protein acetylation.  Interestingly, we found that the 
metabolically-sensitive deacetylase, sirtuin 1 (Sirt1), is a direct regulator of 14-3-3ζ 
acetylation and demonstrated that a loss of Sirt1 activity in aging Xenopus egg extracts 
contributes to 14-3-3ζ release and activation of caspase-2 (Andersen et al., 2011).  As an 
NAD+ dependent deacetylase, Sirt1 activity can be regulated by the availability of this 
metabolite co-factor.  As such, Sirt1 is typically activated by starvation conditions (i.e., 
increased NAD+/NADH ratios), rather than nutrient excess.  Given this, we were 
surprised to observe a decrease in Sirt1 activity upon extract incubation, when nutrient 
levels were thought to be decreasing.  Given the inconsistencies between Sirt1 activity 
and the extract starvation hypothesis, we became interested in investigating the 
metabolic stress triggering caspase-2 activation in our cell-free extract system.   
In an attempt to more thoroughly understand the metabolic changes underlying 
caspase-2 activation in this setting, we performed metabolomic profiling on egg extract 
at time points leading up to caspase-2 activation.  Consistent with previous studies on 
egg metabolism, we observed a robust decrease in aspartate upon extract incubation, 
indicating the usage of amino acids as a fuel source in this cell type (Dworkin and 
Dworkin-Rastl, 1990, 1991).  The most notable change preceding caspase-2 activation, 
however, was a marked increase in LCFA metabolites.  Metabolic treatments that 
suppress caspase-2 activation specifically block the observed increase in LCFA 
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metabolites, suggesting that a buildup of lipids may engage the apoptotic 
pathway/caspase-2 in Xenopus egg extract.  Moreover, the caspase-suppressive effect of 
such metabolic treatments could be overridden by supplementing the extract with the 
saturated LCFA, palmitate.  Together, these data provide evidence that lipid 
accumulation plays a critical role in triggering caspase-2 activation and apoptosis in 
Xenopus egg extract. 
3.2 Results 
Active caspase-2 has been shown to trigger mitochondrial cytochrome c release 
in a number of settings and our lab has shown that it is required upstream of 
mitochondria to induce cell-free apoptosis in the Xenopus egg extract system (Nutt et al., 
2005).   We initially observed that activation of caspase-2 in this setting could be blocked 
by supplementing egg extract with metabolic intermediates, suggesting that metabolic 
changes preceded caspase-2 activation.  However, the precise nature of these metabolic 
changes was unclear.  Thus, in an effort to understand the mechanisms underlying 
caspase-2 activation, we performed metabolomics on Xenopus egg extract, comparing 
fresh, unaged extract to extract incubated at room temperature for several hours and 
harvested just prior to caspase-2 activation (aged).  All samples were analyzed for amino 
acid, organic acid, and acylcarnitine changes. 
  
66 
3.2.1 Amino acid metabolism and the accumulation of succinate 
precede caspase activation in Xenopus egg extract 
In agreement with previous studies on egg metabolism, the two most abundant 
amino acids in Xenopus egg extract were aspartate and glutamate (Shiokawa et al., 1986; 
Vastag et al., 2011).  Interestingly, upon room temperature incubation of the extract, we 
observed a notable decrease in aspartate, along with a corresponding increase in alanine, 
with very little change in the other amino acids profiled (Figure 3.1A).  These changes 
are likely occurring via transamination reactions, whereby aspartate is converted to 
oxaloacetate and pyruvate is converted to alanine via transamination of α-ketoglutarate 
and glutamate, respectively (Figure 3.1B).  The decrease in aspartate suggests that this 
amino acid is likely serving as a carbon source to support extract metabolism, as has 
previously been shown in intact Xenopus eggs (Dworkin and Dworkin-Rastl, 1990).  We 
also observed changes in the organic acid profile of fresh and aged extracts, including an 
increase in both pyruvate and lactate following extract incubation (Figure 3.1C).  In 
contrast, intermediates of the TCA cycle decreased moderately, with the exception of 
succinate, which showed significant accumulation (Figure 3.1C).   
Increased levels of succinate are often observed under conditions in which the 
electron transport chain (ETC) is inhibited (Folbergrova´ et al., 1974; Kotarsky et al., 
2012; Wiesner et al., 1989).  Hypoxia, or the lack of oxygen, has been shown to inhibit 
ETC function, as well as result in increased levels of succinate.  Interestingly, under 
hypoxic conditions, the formation of succinate has been shown to be coupled to amino 
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acid utilization, specifically that of aspartate and glutamate (Hochachka et al., 1975; 
Taegtmeyer, 1978).  Given the similarities between these observations and our data, we 
wanted to determine whether there were any other metabolic changes that might 
indicate a loss of mitochondrial respiration.   
  
68 
0
200
400
600
800
1000
1200
1400
n
m
o
l/
m
L 
h
o
m
o
ge
n
at
e
A
B
C
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
Pyruvate
μ
M
0
200
400
600
800
1000
1200
1400
1600
Lactate
μ
M
0
50
100
150
200
250
Succinate Fumarate Malate α-Ketoglutarate Citrate
μ
M
 
Figure 3.1: Amino acid metabolism and the accumulation of succinate precede caspase 
activation in Xenopus egg extract.   
 
Figure 3.1: A. Freshly prepared Xenopus egg extract (dark gray bars) or extract incubated at 
room temperature for 4 h (light gray bars) was analyzed for amino acid profile following 
protein precipitation.  B. Figure of carbon flux via transamination reactions in the egg extract.  
C.  Egg extracts, treated as in panel A, were analyzed for organic acids.   
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3.2.2 The absence of mitochondrial respiration in incubated extract 
results in the accumulation of long-chain acylcarnitines and a 
decrease in the NAD+/NADH ratio 
Since ETC inhibition results in a block in beta-oxidation and a decrease in the 
NAD+/NADH ratio, we examined both the lipid profile and redox status of incubated 
extract.  Consistent with a lack of ETC function, we observed an accumulation of 
multiple long-chain acylcarnitines, reflective of the long-chain acyl-CoA pools, as well as 
a progressive decrease in the NAD+/NADH ratio following extract incubation (Figure 
3.2A and 3.2B).  Furthermore, since changes in the cytosolic levels of NADH and NAD+ 
are reflected in the balance between lactate and pyruvate, we assessed the 
lactate/pyruvate ratio and found that the ratio was significantly increased from 17.3 to 
188.7 in aged extracts, supporting the observed accumulation of NADH.   
Given these data, we wanted to more directly assess whether the extract might 
be experiencing hypoxia.  Rather than assessing the dissolved oxygen content in the 
extract as a readout of hypoxia, as it would be hard to define what dissolved oxygen 
percentage in egg extracts would result in hypoxic phenotypes, we chose to more 
directly assess mitochondrial respiration.  Using the Seahorse Bioscience XF24 
extracellular flux analyzer, we monitored the O2 consumption rate of aging egg extracts 
for 4 h.  Indeed, extracts showed little O2 consumption, with respiration going to 
virtually zero over time (Figure 3.2C).   
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Figure 3.2: The absence of mitochondrial respiration results in the accumulation of 
long-chain acylcarnitines and a decrease in the NAD+/NADH ratio 
 
Figure 3.2: A. Freshly prepared Xenopus egg extract (dark gray bars) or extract incubated at 
room temperature for 4 h (light gray bars) was analyzed for acylcarnitines.  B. Samples of egg 
extract were collected at the indicated times and analyzed for NAD+/NADH ratio changes by 
spectrophotometric color change (kit supplied by BioVision).  The same samples were used to 
measure caspase-3 activity using the caspase substrate Ac-DEVD-pNA.  Substrate cleavage 
was measured spectrophotometrically at 405 nm.  F. The O2 consumption rate of aging egg 
extracts was monitored for 4 h using the Seahorse Bioscience XF24 extracellular flux 
analyzer.  The results represent the means ± S.D. of three technical replicates. 
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Together, these data suggest that the observed metabolic changes are linked to 
inhibited mitochondrial respiration, including the formation of succinate from the amino 
acid aspartate, the build-up of NADH, and the accumulation of LCFA metabolites 
(acylcarnitines/acyl-CoAs).  Since we knew from previous studies that the activation of 
caspase-2 and downstream apoptotic events could be blocked in this system by 
supplementing the extract with metabolites (Nutt et al., 2005), we postulated that one of 
these underlying metabolic changes might be triggering caspase-2 activation. 
3.2.3 Inhibition of amino acid transamination by aminooxyacetate 
blocks caspase activation 
Given the potential dependence of the egg extract on amino acid utilization and 
previous observations that hypoxia-induced succinate formation could be abrogated by 
inhibiting transamination reactions (Taegtmeyer, 1978), we wanted to determine 
whether the inhibition of transaminase activity would affect caspase activation in the 
extract.  To test this, we treated the extract with the general transaminase inhibitor, 
aminooxyacetate (AOA), and monitored caspase-2 activity via cleavage of the model 
substrate, VDVAD-pNA, over time.  Surprisingly, the inhibition of transaminase activity 
suppressed VDVAD cleavage activity in the extract (Figure 3.3A; note that the absolute 
time course of caspase activation varies from extract to extract, but the relative rates of 
caspase activation following different treatments is constant).  We also found that 
caspase-2 processing, which occurs following caspase-2 activation as a means to stabilize 
the active dimeric protease, was suppressed by AOA treatment (Figure 3.3B).  
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Furthermore, downstream activation of the executioner caspase, caspase-3, was also 
suppressed by AOA treatment (Figure 3.3C), suggesting that the loss of amino acid 
transamination can suppress caspase activation in the extract. 
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Figure 3.3: The inhibition of amino acid transamination by aminooxyacetate 
blocks caspase activation 
 
Figure 3.3: A. Egg extracts supplemented with AOA (10 mM) or buffer were analyzed for 
caspase-2 activity at the indicated time points using the BioVision caspase-2 colorimetric 
assay kit B. 35S‐labeled caspase-2 was incubated in AOA- or mock‐treated extracts and 
samples were resolved by SDS‐PAGE/phosphorimager.  C. Egg extracts, treated as in panel 
A, were analyzed for caspase-3 activity at the indicated time points using the caspase 
substrate Ac-DEVD-pNA.  
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3.2.4 Metabolic treatments that block caspase activation also prevent 
the accumulation of long-chain fatty acid metabolites 
 In an effort to understand how inhibition of amino acid transamination can 
suppress caspase activation, we compared the metabolic profiles of extracts treated with 
and without AOA.  AOA caused aspartate and alanine levels to return to basal levels in 
aged extracts, consistent with our suggestion that the changes in these amino acids are 
driven by aspartate transamination and further catabolism (Figure 3.4A).  Treatment of 
extracts with AOA caused a substantial decrease in TCA cycle intermediates and 
blocked the accumulation of succinate, suggesting that aspartate plays an important role 
in energy metabolism, particularly in supplying the extract with anaplerotic substrates 
(Figure 3.4B).  Glycolytic activity appeared to be unaffected by transaminase inhibition, 
as demonstrated by the accumulation of pyruvate and lactate in the presence of AOA 
(Figure 3.4B).  Strikingly, we observed a decrease in long-chain acylcarnitine 
accumulation in the presence of AOA, suggesting that inhibition of amino acid 
transamination was able to suppress the increase in LCFA metabolites (Figure 3.4C).   
Since LCFA accumulation may be linked to redox changes in the extract (i.e. high 
levels of NADH inhibits the oxidation of LCFAs), we assessed whether AOA could 
modify the observed decrease in the NAD+/NADH ratio preceding caspase activation.  
As shown in Figure 3.4D, AOA was able to delay the decrease in NAD+/NADH, 
supporting the notion that acylcarnitine accumulation may be resulting from increasing 
levels of NADH, which can then feedback to inhibit beta-oxidation.  Although we  
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Figure 3.4: Metabolic treatments that block caspase activation also prevent the 
accumulation of long-chain fatty acid metabolites 
 
Figure 3.4: A. Amino acid profiling was performed on egg extracts immediately following 
preparation (black bars) or after room temperature incubation in the absence (light gray bars) 
or presence of 10 mM AOA (dark gray bars).  B. Egg extracts, treated as in panel A, were 
analyzed for organic acids.  C. Egg extracts, treated as in panel A, were analyzed for 
acylcarnitines.  D. Samples of egg extract treated with and without 10 mM AOA were 
collected at the indicated times and analyzed for NAD+/NADH ratio changes by 
spectrophotometric color change (kit supplied by BioVision).   
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observed a delay of NADH accumulation in AOA-treated extracts, the lactate/pyruvate 
ratio was still increased in comparison to fresh extracts.  Although there may be some 
effect of AOA on cytosolic NAD+/NADH pools, as there is delayed accumulation of 
lactate (Figure 3.4B), it is more likely that AOA is blocking the mitochondrial shift of 
NAD+ to NADH by inhibiting TCA cycle flux.  This, in turn, may delay the decrease in 
total NAD+/NADH. 
3.2.5 Supplementation of the extract with glucose-6-phosphate blocks 
long-chain fatty acid metabolite accumulation  
The ability of AOA to both suppress caspase activation and block significant 
metabolic changes in the extract, including the catabolism of aspartate and the 
accumulation of long-chain acylcarnitines, suggests that one or both of these metabolic 
alterations is necessary for caspase-2 activation (and thus downstream caspase-3 
activation) in this system.  To further investigate this, we examined the metabolic profile 
of egg extract treated with a pentose phosphate pathway intermediate, G6P, which we 
have previously shown can suppress caspase-2 activation in this setting (Nutt et al., 
2005).  While G6P was able to block the accumulation of long-chain acylcarnitines, it was 
unable to suppress aspartate transamination and succinate formation (Figure 3.5 A and 
B).  Collectively, these data suggest that the accumulation of LCFA metabolites is the 
pivotal metabolic change underlying caspase-2 activation.  Moreover, the previously 
observed protection from apoptosis in egg extracts conferred by G6P may be mediated, 
at least in part, by preventing the accumulation of LCFAs.  These findings raise the 
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interesting possibility that caspase-2 is, more broadly, an initiator caspase for 
lipoapoptosis. 
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Figure 3.5: Supplementation of the extract with glucose-6-phosphate blocks long-
chain fatty acid metabolite accumulation 
 
Figure 3.5: A. Amino acid profiling was performed on egg extracts immediately following 
preparation (black bars) or after room temperature incubation in the absence (light gray bars) 
or presence of 20 mM G6P (dark gray bars).  B. Egg extracts, treated as in panel A, were 
analyzed for acylcarnitines.   
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3.2.6 Palmitate accelerates caspase activation and overrides the 
protective effect of AOA 
Given the data above and previous publications implicating LCFAs in cell death, 
we were interested in determining whether treatment of the extract with an LCFA that 
increased in abundance with extract incubation (palmitate, C16) might accelerate 
caspase activation (Arici et al., 2003; de Vries et al., 1997; El-Assaad et al., 2003; Lupi et 
al., 2002; Malhi et al., 2006) (Figure 3.2A and 3.4C).  To test this, we treated extracts with 
BSA-conjugated palmitate or BSA as a control and performed a caspase activity assay.  
As shown in Figure 3.6A, palmitate accelerated caspase-3 activation, and this 
acceleration could be blocked by the addition of the anti-apoptotic protein, B cell 
lymphoma XL (Bcl-xL), suggesting that palmitate is specifically engaging the apoptotic 
pathway upstream of mitochondria.  Furthermore, we verified that the pro-apoptotic 
effect of palmitate was being exerted at the level of caspase-2 by monitoring enzyme 
processing and found that it was, indeed, accelerated after palmitate treatment (Figure 
3.6B).  Together, these data suggest that palmitate can promote caspase-2 activation.  
Therefore, we reasoned that if AOA was simply blocking the buildup of LCFAs as a 
means to inhibit apoptosis, then palmitate treatment should be able to override the 
protective effect of AOA.  Indeed, palmitate addition was able to overcome the anti-
apoptotic effect of AOA, accelerating caspase activation (Figure 3.6C).  Taken together, 
these data suggest that an over-abundance of LCFA metabolites can engage the 
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apoptotic pathway in Xenopus egg extract, where caspase-2 is the critical initiator 
caspase.   
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Figure 3.6: Palmitate accelerates caspase activation and overrides the protective effect 
of AOA 
 
Figure 3.6: A. Mock-treated (BSA) or palmitate-treated (BSA-conjugated palmitate, 4 mM) egg 
extracts were incubated in the presence or absence of Bcl-xL and analyzed for caspase-3 
activity at the indicated time points.  Caspase-3 activity was assessed using the caspase 
substrate Ac-DEVD-pNA and cleavage was measured spectrophotometrically at 405 nm.  B. 
35S‐labeled caspase-2 was incubated in mock‐ or palmitate-treated extracts and samples were 
resolved by SDS‐PAGE/phosphorimager.  C. Egg extracts were incubated with combinations 
of palmitate (4 mM) and AOA (10 mM) and caspase-3 activity was assessed using the caspase 
substrate Ac-DEVD-pNA. 
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3.3 Discussion 
Metabolomic profiling of Xenopus egg extract revealed that a clear metabolic 
signature emerges upon extract incubation.  Prior to caspase activation, several robust 
metabolic changes occur, including: a decrease in aspartate with a corresponding 
increase in alanine, an accumulation of succinate, and a buildup of multiple long-chain 
acylcarnitines (which reflect the cognate acyl CoA pools).  While the utilization of amino 
acids as a carbon source was not surprising, as this had been previously observed in 
Xenopus eggs (Dworkin and Dworkin-Rastl, 1990), the buildup of succinate and LCFA 
metabolites was not anticipated- especially given our previous hypothesis that extract 
incubation results in nutrient depletion/starvation that leads to caspase-2 activation.  
Conventionally, cells starved of nutrients (i.e., glucose) activate fatty acid oxidation as a 
means to supply the mitochondria with reducing power, or NADH, for making ATP.  
Therefore, if the extract was, indeed, suffering from nutrient depletion, we would expect 
to see a decrease in fatty acid levels following extract incubation, which is not what was 
observed.  Rather, the metabolic profile of incubated extract showed striking similarity 
to previous studies of hypoxic systems.  Thus, we measured mitochondrial oxygen 
consumption and discovered that extracts fail to consume oxygen during the assessed 
room-temperature incubation period.  Based on previous findings and the lack of 
oxygen consumption in this system, we speculate that the observed metabolic changes 
are the result of inhibited electron transport chain activity, as described below. 
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3.3.1 Potential mechanism of extract metabolism 
A decrease in electron transport chain function or activity would ultimately 
result in a significant decline of oxidized electron carriers (i.e., NAD+).  Furthermore, 
succinate dehydrogenase, which is the only enzyme which participates in both the 
electron transport chain and the TCA cycle, would be unable to efficiently oxidize 
succinate, leading to its accumulation and a decrease in TCA cycle flux.  A block in 
succinate metabolism would cause a decrease in anaplerotic substrates, mainly 
oxaloacetate, resulting in the accumulation of acetyl-CoA (C2) and pyruvate, as we have 
observed in our metabolomics analysis.   
Furthermore, the inefficient flux of substrates through the TCA cycle without the 
ability to efficiently regenerate NAD+ via the ETC would likely lead to a redox 
imbalance, resulting in increased levels of NADH.  A significant shift in the redox status 
of the extract from an oxidized state (NAD+ > NADH) to a reduced state (NADH > 
NAD+) will inhibit glycolytic flux.  Thus, to compensate for such redox changes, 
pyruvate will be converted to lactate, in a process which will regenerate NAD+ from 
NADH.  The large increase in lactate that occurs upon extract incubation is likely driven 
by NADH accumulation.  Furthermore, we speculate that the buildup of LCFA 
metabolites are also linked to increasing levels of NADH which, in combination with 
high levels of acetyl-CoA, can feedback and inhibit beta-oxidation, as well as stimulate 
the process of fatty acid elongation.    
  
81 
3.3.2 Inhibition of extract metabolism and long-chain fatty acid stress  
Our metabolomics data were not consistent with a cellular starvation profile, 
making it unlikely that the stress triggering caspase-2 activation was nutrient depletion.  
As such, we aimed to further understand extract metabolic flux in order to determine 
which of the observed metabolic changes were triggering caspase-2 activation.  Using an 
inhibitor of aminotransferases, we demonstrated that blocking the use of aspartate as a 
carbon source could delay caspase-2 activation in aging extracts.  This effect did not 
appear to be due to amino acid stabilization, but rather appeared to be the result of a 
decrease in LCFA accumulation.   
The ability of AOA to suppress buildup of LCFA metabolites is likely mediated 
by its ability to block carbon flux through the TCA cycle, which helps to stabilize early 
changes in NAD+/NADH (i.e. slowing the decrease we observed in untreated extracts, 
Figure 3D), allowing continued beta-oxidation.  AOA treatment was unable to restore 
mitochondrial respiration (data not shown), making it more likely that AOA is delaying 
NADH accumulation, rather than accelerating NAD+ regeneration.  Palmitate treatment 
can likely override the suppressive effect of AOA by accelerating lipid overload.  The 
ability of palmitate to both accelerate caspase activation and override the suppressive 
effect of AOA suggests that an excess of saturated LCFAs can trigger the activation of 
caspase-2.   
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3.3.3 The extract as a model of metabolic stress  
While the Xenopus egg extract metabolomics may not reflect the metabolic state 
of unstressed mammalian cells, the observed metabolic signature was very reminiscent 
of several pathophysiological disease states.  For example, succinate and LCFA 
accumulations have been observed in hypoxia, diabetes, and cancer and have been 
attributed to an imbalance between energy demand and food/oxygen supply (Goldberg 
et al., 1966; Sadagopan et al., 2007; Selak et al., 2005).  Although the underlying cause of 
such an imbalance remains uncertain in the extract, we hypothesized that the critical 
metabolic stress triggering caspase-2 activation and apoptosis was the accumulation of 
LCFAs.   
The accumulation of LCFA metabolites in hypoxia has been appreciated for some 
time.  Interestingly, caspase-2 has recently gained recognition as a regulator of hypoxia-
induced toxicity in several models, including porcine proximal tubule cells (LLC-PK1), 
human neuroblastoma cells (SK-N-MC), and neonatal mouse brains (Carlsson et al., 
2011; Carlsson et al., 2012; Nakagawa et al., 2008; Park et al., 2007b).  Given our data, it 
seems likely that the buildup of LCFA metabolites in these hypoxic settings may be 
triggering the activation of caspase-2.  Interestingly, these studies highlight a potential 
correlation between lipid accumulations and caspase-2 activation which warrants 
further investigation.  Looking specifically at whether caspase-2 can function as a more 
general initiator of cell death in response to lipotoxicity, specifically in mammalian cell 
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systems, is an important step toward furthering this research.  Chapter 4 of this thesis 
discusses our work to address this question.   
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4. Caspase-2 as an initiator of lipid-induced cell death in 
mammalian cells  
This chapter appears in modified form in the Journal of Biological Chemistry. 
2013 May 17; 288(20): 14463-75. 
4.1 Introduction 
During periods of overnutrition, LCFAs accumulate to levels that exceed the 
storage capacity of adipose tissue.  As a result, LCFAs become elevated in the plasma, 
resulting in increased import and storage of these molecules in non-adipose tissues 
(Frayn, 2002; Kusminski et al., 2009; Lewis et al., 2002).  The over-accumulation of lipids 
in non-adipose tissues can be toxic, resulting in chronic cellular dysfunction and 
ultimately apoptotic cell death, a process more generally referred to as lipoapoptosis.  
Lipoapoptosis can profoundly compromise tissue function and appears to be an 
underlying cause of diseases associated with metabolic syndrome (Cazanave and Gores, 
2010; Kusminski et al., 2009; Listenberger and Schaffer, 2002; Unger et al., 2010).  
LCFA-induced lipoapoptosis has been shown to occur in many cell types, 
including hepatocytes, cardiomyocytes, proximal tubule cells in the kidney, and islet 
beta cells in the pancreas (Arici et al., 2003; de Vries et al., 1997; El-Assaad et al., 2003; 
Malhi et al., 2006).  These cells, which specifically undergo apoptosis in response to 
treatment with saturated fatty acids, display several characteristic features of the 
intrinsic apoptotic pathway, including mitochondrial permeabilization, cytochrome c 
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release, and effector caspase activation (Unger and Orci, 2002).  While the role of the 
intrinsic apoptotic pathway has been well-established in LCFA-induced apoptosis, the 
core apoptotic machinery engaged by toxic concentrations of saturated LCFAs upstream 
of the mitochondria has not yet been revealed. 
Accumulating evidence suggests that caspase-2 is not universally engaged by 
apoptotic signaling pathways but instead responds to specific cellular stressors.  Given 
our findings on caspase-2 activation and LCFA accumulation in Xenopus egg extract, we 
aimed to determine whether caspase-2 might be mediating lipoapoptosis in mammalian 
somatic cells.  Our data suggest that caspase-2 is, indeed, activated upon LCFA 
treatment in mammalian cells.  We demonstrate that caspase-2 shifts into a high 
molecular weight complex following the treatment of HEK 293T cells with the saturated 
LCFA, palmitate.  Down-regulation of caspase-2 also significantly impairs cell death 
induced by saturated LCFA treatment, suggesting that caspase-2 activates LCFA-
induced lipoapoptosis in mammalian cells.  These findings, which reveal a conserved, 
critical role for caspase-2 as an initiator of lipoapoptosis, may have clinical implications 
for the treatment of diseases associated with lipid accumulations. 
4.2 Results 
4.2.1 Caspase-2 plays a central role in mediating lipotoxicity in 293T 
cells 
With ample evidence showing that palmitate can induce cell death in a number 
of mammalian cell lines at physiologically relevant concentrations (0.03-1.0 mM) 
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(Furstova et al., 2008), we first wished to extend our observations from the Xenopus egg 
extract system and determine whether caspase-2 is activated in lipid-induced apoptosis 
in mammalian cells.  To test this, we transfected HEK 293T cells with siRNA directed 
against caspase-2 or a scrambled siRNA control and then treated cells with 1 mM 
palmitate for 18 h.  We then assessed caspase-2 activation via cleavage of the model 
substrate, VDVAD-pNA, and found that the enzymatic activity of caspase-2 was 
increased following palmitate treatment (Figure 4.1A).  The observed increase in activity 
appears to be specific to caspase-2, as knockdown of the protease was able to block the 
palmitate-induced increase in substrate cleavage (Figure 4.1A).  Additionally, since 
caspase-2 has been shown to undergo proteolytic processing following its activation in 
mammalian cells, we also monitored caspase-2 cleavage via western blot and found that 
caspase-2 was processed following palmitate treatment (Figure 4.1B). 
As an initiator caspase, caspase-2 is activated following the binding of adaptor 
proteins, which facilitate its oligomerization into a high molecular weight (HMW) 
complex.  Therefore, to determine whether caspase-2 is engaged and activated in this 
fashion during LCFA-induced apoptosis, we performed gel filtration analysis on HEK 
293T cell extracts derived from control and palmitate-treated cells.  While we 
consistently observed trace amounts of caspase-2 in the HMW fractions of mock treated 
cells, in palmitate treated cells, recruitment of caspase-2 into HMW fractions was robust 
  
87 
(Figure 4.1C).  We further confirmed that the caspase-2 present in these HMW fractions 
was, indeed, enzymatically active by performing a caspase-2 activity assay (Figure 4.1C). 
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Figure 4.1: Caspase-2 plays a central role in mediating lipotoxicity in 293T cells 
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Finally, we confirmed the activation of caspase-2 in situ following palmitate 
treatment using BiFC (Bouchier-Hayes et al., 2009).  To do this, we stably transfected 
HeLa Tet-Off cells with a construct encoding a caspase-2 prodomain fused to each of the 
split Venus proteins and under the control of a central, bidirectional tetracycline-
response element (TRE).  These cells were allowed to express the constructs in DMEM 
supplemented with tetracycline-free FBS for 24 h and then treated with 1 mM palmitate 
and 10 μM Q-VD-OPh, to block downstream executioner caspase activation, for 24 h.  As 
expected, we obtained a strong BiFC signal with caspase-2/prodomain constructs 
following palmitate treatment (Figure 4.1D), suggesting that caspase-2 is dimerized and 
activated in mammalian cells in response to palmitate-induced lipotoxicity.  
Figure 4.1: A. 293T cells were transfected with 50 nM scrambled or C2‐targeted siRNA.  At 48 
h post-transfection, cells were mock-treated with BSA or treated with 1 mM palmitate for 18 h 
and caspase-2 activity was assessed using the BioVision caspase-2 colorimetric assay kit.  
Knockdown efficiency was determined by immunoblot.  The results represent the means ± 
S.E. for percent increase in activity compared to siCTRL, mock-treated samples for three 
independent experiments.  Statistical significance was determined using a two-tailed 
Student’s t test.  *, p < 0.05 versus control.  B. 293T cells were treated with BSA or palmitate for 
24 h and immunoblotted for caspase-2 and actin.  The top caspase-2 panel is a short exposure 
(to show changes in full length caspase-2 levels) and the bottom caspase-2 panel is a long 
exposure (to reveal the p12 fragment).  C. 293T cells were treated with BSA or palmitate for 18 
hours before lysis by dounce homogenization in hypotonic lysis buffer.  Cell lysates were 
separated on a Superdex 200 column and relevant fractions were immunoblotted for caspase-
2.  Full length caspase-2 and processed caspase-2 are indicated.  Fractions were also tested for 
caspase-2 activity by assessing cleavage of the caspase-2 model substrate, VDVAD-pNA, as 
part of the BioVision caspase-2 colorimetric assay kit.  D. 293T cells were treated as in panel A 
and at 24 h post-treatment, phase-contrast images were captured on an EVOS FL digital 
inverted microscope.  E. 293T cells were treated as in panel A and cell death was measured 24 
h after palmitate treatment by propidium iodide staining and flow cytometric analysis.  The 
results represent the means ± S.E. for four independent experiments.   
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We next wanted to determine whether caspase-2 was required for lipoapoptosis 
in mammalian cells.  To do this, we treated scrambled or caspase-2 knockdown cells 
with palmitate for 24 h before measuring cell viability.  Palmitate induced significant cell 
death in the scrambled control cells, whereas caspase-2 deficient cells were protected 
from apoptosis, as shown by maintenance of cell density over 24 h of treatment (Figure 
4.1E).  We further quantified cell death by PI staining and found that down-regulation of 
caspase-2 could significantly block palmitate-induced cell death in 293T cells (Figure 
4.1F), suggesting that caspase-2 is required for lipoapoptosis in these cells. 
4.2.2 Caspase-2 mediates saturated fatty acid-induced lipoapoptosis 
via acyl-CoA cytotoxicity 
Previous studies have shown in multiple cell types that only saturated LCFAs 
exert cytotoxic effects(de Vries et al., 1997; Furstova et al., 2008; Hardy et al., 2003; Kim 
et al., 2008; Mei et al., 2011; Staiger et al., 2006).  Therefore, we wanted to determine 
whether caspase-2 was required for cell death induced by other saturated LCFAs, as 
well as validate that only saturated LCFAs could induce apoptosis.  To do this, we 
treated scrambled or caspase-2 knockdown cells with either the monounsaturated fatty 
acids, palmitoleate (16:1) and oleate (18:1), or the saturated fatty acids, palmitate (16:0) 
and stearate (18:0).  Cell death was assessed by PI staining.  As expected, only saturated 
fatty acids induced prominent cell death (Figure 4.2A).  Interestingly, the loss of caspase-
2 was able to significantly protect against cell death induced by both saturated LCFAs, 
suggesting that caspase-2 can function as a general initiator of cell death in saturated 
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fatty acid-induced lipotoxicity (Figure 4.2A).  Moreover, since the combination of 
saturated and unsaturated fatty acids has been shown to reduce the cytotoxic effects of 
saturated fatty acids (Coll et al., 2008; Gao et al., 2009; Listenberger et al., 2003; Miller et 
al., 2005; Yuzefovych et al., 2010), we also assessed whether oleate addition could protect 
against caspase-2 mediated cell death induced by palmitate or stearate.  Consistent with 
previous findings, oleate was able to block cell death induced by these saturated fatty 
acids, suggesting that it could prevent palmitate and stearate-induced caspase-2 
activation (Figure 4.2A).   
In some settings, the ability of oleate to suppress the cytotoxic effects of saturated 
LCFAs has been attributed to its ability to decrease palmitate-induced ROS and 
ceramide generation (Hu et al., 2011; Yuzefovych et al., 2010).  To test whether the cell 
death induced by palmitate in 293T cells was being mediated by either of these two 
stresses, we treated cells with the ROS scavenger, N-acetyl cysteine (NAC), or the serine 
palmitoyltransferase inhibitor, myriocin, to inhibit ceramide synthesis.  Neither 
treatment was able to suppress cell death induced by palmitate, suggesting that 
palmitate-induced apoptosis is not dependent on ROS or ceramide formation in these 
cells (data not shown).  Thus, in order to more thoroughly understand how palmitate 
exerts its pro-apoptotic effects on caspase-2, we tested whether metabolism of palmitate 
to its corresponding long-chain acyl-CoA and/or long-chain acylcarnitine form was 
required to induce caspase-2 activity and cell death.   
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Activation of other caspases, specifically caspase-3, -7, and -8, has been shown to 
be directly induced by palmitoylcarnitine in vitro (Mutomba et al., 2000), and therefore, 
it seemed possible that caspase-2 was being activated by palmitate via its conversion to 
palmitoylcarnitine.  To explore this possibility, we treated cells with the long-chain acyl-
CoA synthetase inhibitor, triacsin C, and the carnitine palmitoyltransferase I inhibitor, 
etomoxir, and assessed caspase-2 activity following palmitate treatment.  Triacsin C, 
which inhibits the formation of palmitoyl-CoA, significantly prevented palmitate-
induced caspase-2 activation, while etomoxir, which inhibits the formation of 
palmitoylcarnitine, had no significant effect (Figure 4.2B).  Consistent with caspase-2 
being the initiator of apoptosis in this setting, triacsin C was also able to inhibit cell 
death, while etomoxir failed to show any effect (Figure 4.2C).  Together, these data 
suggest that while palmitate activation via acyl-CoA formation was essential to induce 
caspase-2 activation, palmitoylcarnitine formation was not required.  It is important to 
note that in our experimental setting, triacsin C revealed cytotoxic effects in the absence 
of palmitate, which may be due to a reduction of basal intracellular acyl-CoA 
concentrations below a level necessary for cell viability (data not shown).   
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Figure 4.2 Caspase-2 mediates saturated fatty acid-induced lipoapoptosis via acyl-CoA 
cytotoxicity 
 
4.2.3 Caspase-2 is required for LCFA-induced apoptosis in 
hepatocytes 
To more thoroughly evaluate the importance of caspase-2 in lipoapoptosis, we 
examined the role of caspase-2 in saturated LCFA-induced hepatocyte cell death.  
Accumulating evidence suggests that lipoapoptosis plays an important role in the 
Figure 4.2: A. 293T cells were transfected with 50 nM scrambled or C2‐targeted siRNA.  At 48 
h post-transfection, cells were mock-treated with BSA or 1 mM fatty acids and cell death was 
measured 24 h post-treatment by propidium iodide staining and flow cytometric analysis.  
The results represent the means ± S.E. for four independent experiments.  Statistical 
significance was determined using a two-tailed Student’s t test.  **, p < 0.01 versus control.  B. 
293T cells were mock-treated with BSA or treated with 1 mM palmitate with or without 200 
μM etomoxir or 5 μM triacsin C.  At 24 h post-treatment, phase-contrast images were 
captured on an EVOS FL digital inverted microscope.  C. 293T cells were treated as in B.  At 18 
h post-treatment, caspase-2 activity was assessed using the BioVision caspase-2 colorimetric 
assay kit.  The results represent the means ± S.E. for percent increase in activity compared to 
mock-treated samples for four independent experiments.  Statistical significance was 
determined using a two-tailed Student’s t test.  *, p < 0.05 versus control. 
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pathogenesis of NAFLD, specifically in the progression from NAFLD to the more 
advanced state of liver disease, NASH (Cazanave and Gores, 2010; Ibrahim et al., 2011).   
To determine whether caspase-2 is required for lipoapoptosis in hepatocytes, we 
tested whether knockdown of caspase-2 in HepG2 cells would protect against palmitate-
induced cell death.  As shown in Figure 4.3A, down-regulation of caspase-2 was able to 
dampen cell death, as determined by PI staining.  While the decrease in cell death is 
clear upon caspase-2 knockdown, it is not complete.  The lack of a larger effect may be 
due to residual caspase-2, as we were only able to achieve partial knockdown in this cell 
type (Figure 4.3A).  Therefore, we also investigated whether caspase-2 was activated in 
normal mouse hepatocytes (AML12 cells) following palmitate treatment by measuring 
VDVAD-pNA cleavage.  We observed a 45% increase in enzymatic activity, consistent 
with a role for caspase-2 in palmitate-induced cell death in hepatocytes (data not 
shown).  To determine whether caspase-2 was required for cell death, we pre-treated 
AML12 cells with scrambled or caspase-2 siRNA and assessed cell death after palmitate 
treatment.  Down-regulation of caspase-2 significantly inhibited cell death in these 
normal mouse hepatocytes (Figure 4.3B), revealing a conserved, critical role for caspase-
2 in saturated LCFA-induced cell death.  
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Figure 4.3: Caspase-2 is required for LCFA-induced apoptosis in hepatocytes 
 
Figure 4.3: A. HepG2 cells were transfected with 50 nM scrambled or C2‐targeted siRNA.  At 
48 h post-transfection, cells were mock-treated with BSA or treated with 0.7 mM palmitate for 
24 h and cell death was measured by propidium iodide staining and flow cytometric analysis.  
Knockdown efficiency was determined by immunoblot.  B. AML12 cells were treated with 50 
nM scrambled or mouse caspase-2-targeted smartpool siRNA.  At 48 h post-transfection, cells 
were mock- or palmitate-treated and analyzed for cell death as in panel A.  Knockdown 
efficiency was determined by immunoblot.  The results represent the means ± S.E. for three or 
more independent experiments.  Statistical significance was determined using a two-tailed 
Student’s t test.  *, p < 0.05 versus control. **, p < 0.01 versus control. 
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4.3 Discussion 
With the prevalence of obesity and metabolic syndrome rising sharply world-
wide, it has become increasingly important to define the molecular mechanisms 
underlying the pathogenesis and progression of diseases associated with lipid-induced 
cytotoxicity.  Cardiovascular disease, type-2 diabetes mellitus (T2DM), and NAFLD 
have all recently gained recognition as diseases that are exacerbated by lipoapoptosis 
(Cazanave and Gores, 2010; Kusminski et al., 2009; Listenberger and Schaffer, 2002).  In 
this chapter, we demonstrated that caspase-2 is not only engaged, but makes a 
significant contribution to saturated LCFA-induced cell death both in 293T cells and 
several hepatocyte cell lines.  Together, these findings reveal a previously unknown role 
for caspase-2 as an initiator caspase and provide a missing link in the signaling 
pathways functioning upstream of the mitochondria in lipoapoptosis.  The relevance 
and potential impact of this novel finding are discussed below.   
4.3.1 Caspase-2 initiates saturated LCFA-induced lipoapoptosis in 
293T cells 
Our data suggest that caspase-2 is activated in 293T cells following palmitate 
treatment as shown by both cleavage of the preferred caspase-2 substrate, VDVAD, as 
well as proteolytic processing of the caspase-2 proenzyme.  We also verified that 
caspase-2 is activated following palmitate treatment by recruitment to a HMW complex 
and that only the HMW fractions containing caspase-2 exhibited enzymatic VDVAD 
cleavage activity.  Caspase-2 was also required for full activation of palmitate-induced 
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cell death, specifically in HEK 293T cells.  Delving further into caspase-2-induced 
lipotoxicity, we confirmed that only saturated fatty acids induced cell death and that this 
cell death was dependent on caspase-2.  Interestingly, as has previously been observed 
in other cells types, palmitate-induced cytotoxicity was not dependent on ROS, 
ceramides, or oxidative LCFA catabolism in our 293T cell model (Hardy et al., 2003; Kim 
et al., 2008; Staiger et al., 2006).  Rather, the activation of palmitate via acyl-CoA 
formation was required to induce cell death.  Understanding how saturated LCFAs and 
their respective acyl-CoA derivatives induce caspase-2 is the focus of ongoing studies.   
Currently, we are testing the hypothesis that conversion of palmitoyl-CoA into 
lysophosphatidylcholine (LPC), which functions as a minor phospholipid in cellular 
membranes, could be mediating caspase-2 activation by acting as the toxic effector.  
Recent findings in the literature have suggested that palmitate toxicity is exerted 
indirectly via generation of the lipid metabolite, LPC (Han et al., 2008; Kakisaka et al., 
2012).  Upregulation of LPC can change plasma membrane lipid dynamics and activate 
apoptosis by influencing signaling pathways via the activation of JNK, GSK-3, and/or 
PKC (Kakisaka et al., 2012; Masamune et al., 2001).  Although the data have not been 
included in this thesis, we have preliminary data which suggests that caspase-2 is 
necessary for cell death in response to LPC.  Caspase-2 knockdown cells treated with 
LPC are significantly protected from cell death, suggesting that LPC may be the 
downstream effector of palmitate that activates caspase-2 and results in apoptosis.  The 
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conversion of phosphatidylcholine to lysophosphatidylcholine downstream of palmitate 
treatment can be inhibited by blocking the activity of phospholipase A2.  Future studies 
will evaluate whether inhibition of this lipase can protect against palmitate-induced cell 
death, which would suggest that the formation of saturated LPC from palmitate is 
responsible for caspase-2 activation in our cell model of lipoapoptosis.   
4.3.2 Implications for hepatocyte lipoapoptosis and NAFLD/NASH 
In addition to HEK 293T cells, we also showed that caspase-2 could function as 
an initiator of cell death in hepatocytes treated with saturated LCFAs.  This hepatocyte 
finding is of particular interest, as lipoapoptosis plays a critical role in the development 
and progression of NAFLD, the most common form of chronic liver disease in both 
children and adults in the United States (Browning et al., 2004; Wieckowska and 
Feldstein, 2005).  Furthermore, lipoapoptosis is the key molecular event driving the 
progression of NAFLD to the more advanced state of liver disease, NASH (Feldstein et 
al., 2003; Witek et al., 2009).  Hepatocyte apoptosis is significantly increased in patients 
with NASH and there are currently no effective therapies to halt NAFLD progression.  
Thus, insight into the molecular mediators of lipoapoptosis may be useful in developing 
effective therapies for this syndrome. 
NAFLD is characterized by an increased level of lipids in the liver, which in 
overweight or obese patients, often results from the elevated levels of LCFAs in the 
blood.  The retention of lipids in the liver causes the over-accumulation of cellular lipids 
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in hepatocyte (steatosis) and triggers lipoapoptosis.  Hepatocyte apoptosis results in the 
activation of HSCs and the phagocytosis of apoptotic bodies by HSCs induces their 
production of type I collagen (Canbay et al., 2003).  Collagen secretion by HSCs 
enhances liver fibrogenesis and the development of cirrhosis, both of which correlate 
with negative patient outcomes (Malhi et al., 2010).   
Since apoptosis plays such an important role in NAFLD progression, inhibition 
of apoptosis has been proposed as a useful therapeutic strategy.  In support of this idea, 
recent studies performed in both humans and mice have shown moderate success of 
pan-caspase inhibitors on NAFLD/NASH symptoms (Ratziu et al., 2012; Witek et al., 
2009).  Excitingly, our data suggest that an inhibitor which more specifically targets 
caspase-2 may enhance the effectiveness of caspase-targeted therapies.  The loss of this 
apical initiator caspase doesn’t appear to compromise viability in a knock-out setting 
and thus, caspase-2 is an attractive therapeutic target for both blocking apoptosis and 
maintaining mitochondrial integrity in NAFLD/NASH. 
Finally, while our studies have focused on the importance of caspase-2 in 
hepatocyte lipoapoptosis, there are several additional settings where caspase-2 may be 
relevant in lipoapoptotic therapies, including cardiomyocytes in the heart, proximal 
tubule cells in the kidney, and islet beta cells in the pancreas.  Future studies will 
evaluate the physiological relevance of caspase-2 in these lipotoxicity settings.
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5. Caspase-2 as a regulator of hepatocyte lipoapoptosis 
in a mouse model of nonalcoholic fatty liver disease  
Please note that these experiments were performed in collaboration with Dr. 
Anna Mae Diehl’s laboratory at Duke University.   
5.1 Introduction 
Lipoapoptosis, which is the cell death induced by lipids, plays an important role 
in the pathogenesis of liver disease.  Overnutrition, inactivity, and environment are all 
factors which can increase body fat content, putting you at a higher risk for lipid-
induced toxicity.  For example, in the case of the liver, increasing body fat content results 
in fatty deposits in the liver, and the development of NAFLD.  NAFLD affects 25% of the 
population here in the United States, although many believe this to be an 
underestimation, as patients usually have little to no symptoms often only complaining 
of fatigue or mild abdominal discomfort.  NAFLD is typically diagnosed by abnormal 
liver enzyme levels during routine blood tests, which may indicate that there is a 
decrease in liver function.   
Failure of patients to reduce elevated lipid levels can result in lipid-induced 
apoptosis of hepatocytes and progression of NAFLD to the more advance state of liver 
disease, known as NASH.  A major difference between NAFLD and NASH is the extent 
of hepatocyte apoptosis, which is significantly increased in the case of NASH (Feldstein 
et al., 2003).  NASH is also characterized by fibrosis of the liver and can often lead to an 
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irreversible state of liver cirrhosis.  Once patients have progressed to this state, there is 
little that can be done to reverse liver damage. Therefore, it is important to find a 
therapeutic entry point for halting the progression of NAFLD prior to liver fibrogenesis.   
Hepatocellular apoptosis has been demonstrated to be a critical mechanism 
driving the progression of NAFLD, as well as many other liver diseases, including viral 
hepatitis, Wilson’s disease, cholestatic liver disease, and alcohol-induced injury (Galle 
and Krammer, 1998).  Importantly, the apoptosis observed in these settings has been 
shown to contribute significantly to liver fibrosis through the activation of HSCs, which 
upon transformation to a myofibroblastic state begin secreting type I collagen (collagen 
1α1)(Canbay et al., 2003).  Type I collagen makes up the majority of fibrosis observed in 
liver cirrhosis.  Since lipid-induced apoptosis is a critical mediator of fibrosis in NASH, it 
is important to understand the apoptotic signaling events controlling cell death in order 
to find a potential therapeutic target.   
 The most frequently employed animal model of NASH is a nutritional restriction 
of methionine and choline in the diets of mice.  This model, which is known as the 
methionine-choline deficient diet, or MCD, induces severe liver steatosis by inhibiting 
the secretion of VLDL from the liver.  The retention of fatty acids in the liver results in 
physiological changes similar to those observed in human NASH, including 
aminotransferase elevations, steatosis, hepatocyte apoptosis, and fibrosis (Hebbard and 
George, 2011; Larter and Yeh, 2008; Takahashi et al., 2012).  Although the MCD diet is 
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easy to use, there are some concerns about its efficacy, as the metabolic profile induced 
by the diet goes against what has been observed in individuals with fatty liver.  For 
example, mice fed an MCD diet show significant weight loss, peripheral insulin 
sensitivity, and low insulin and leptin levels (Larter et al., 2008; Leclercq et al., 2007; 
Nagasawa et al., 2006; Rinella and Green, 2004).  Patients with NASH most often have 
symptoms of the metabolic syndrome, including excessive weight gain, insulin 
insensitivity, and high blood pressure.  As such, this diet should only be used to assess 
changes in liver injury and repair pathways and should not be used to evaluate the 
impact of experimental treatments on metabolic status.  
Since lipid-induced apoptosis is critical for NASH and our data suggest that 
caspase-2 can function an initiator of lipoapoptosis, we hypothesized that caspase-2 
might play a role in the development of NASH in vivo.  To test this hypothesis, we 
assayed caspase-2 protein levels following MCD diet feeding as well as determined 
whether caspase-2 KO mice were protected from hepatocyte lipoapoptosis and fibrosis.  
Interestingly, we found that caspase-2 protein levels were significantly increased after 
an 8-week MCD diet regimen.  This was consistent with what we observed in NASH 
patients, where caspase-2 was also upregulated.  Moreover, we show that caspase-2 KO 
mice fed the MCD diet are protected from apoptosis, HSC activation, and fibrosis.  These 
data provide substantial evidence that caspase-2 is a potential therapeutic target for both 
blocking apoptosis and preventing fibrogenesis in NAFLD/NASH.   
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5.2 Results 
5.2.1 Caspase-2 KO hepatocytes are protected from palmitate- 
induced apoptosis in vitro  
In Chapter 4, we discussed our data demonstrating that caspase-2 is a critical 
regulator of lipoapoptosis in mammalian cells.  We aimed to further validate these 
findings using a genetic model of caspase-2 depletion and thus, we tested whether 
caspase-2 KO hepatocytes were protected against a palmitate-induced death in vitro.  To 
do this, we isolated hepatocytes from WT or caspase-2 KO C57BL/6J mice and treated 
them with 2% BSA or 2% BSA + 1 mM palmitate for 48 h.  We then assayed hepatocyte 
viability using the cell counting kit-8 and found that while only 35% of WT hepatocytes 
were alive at 48 h, 58% of KO hepatocytes survived (Figure 5.1). The observed increase 
in KO viability further supports a role for caspase-2 in hepatocyte lipoapoptosis.   
0
0.2
0.4
0.6
0.8
1
1.2
WT KO caspase-2
A
b
so
rb
an
ce
 
(f
o
ld
 c
h
an
ge
)
BSA
Palmitate
1 mM
 
Figure 5.1: Caspase-2 KO hepatocytes are protected from palmitate-induced apoptosis 
in vitro 
 
 
Figure 5.1: Hepatocytes isolated from WT or caspase-2 KO mice were treated with BSA or 1 
mM palmitate for 48 h and viability was measured using the cell counting kit-8. 
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5.2.2 Caspase-2 is significantly upregulated in patients with NASH 
and in mice fed an MCD diet 
Given the importance of hepatocyte lipoapoptosis in the pathogenesis of 
NAFLD, we aimed to extend our novel findings from mammalian cells and determine 
whether caspase-2 plays an important role in mediating lipoapoptosis in a mouse model 
of NAFLD.  To test this, we placed WT mice on either a control or MCD diet for 8-weeks.  
We then harvested the livers and assessed caspase-2 protein levels using both 
immunohistochemistry and western blotting.  Unexpectedly, we observed a significant 
increase in hepatic caspase-2 staining in mice fed the MCD diet as compared to the 
control (Figure 5.2 A).  These results were further confirmed by immunoblot, which 
showed that administration of the MCD diet caused significant upregulation of caspase-
2 protein (Figure 5.2 B).  Given this, we were curious whether caspase-2 protein levels 
would be significantly upregulated in patients with NASH.  To examine this, we took 
tissue sections from NASH patients and stained for caspase-2.  Encouragingly, caspase-2 
was upregulated in the livers of patients with NASH just as it was in mice fed an MCD 
diet (Figure 5.2 C).  Taken together, these data demonstrate that caspase-2 is 
significantly upreglated in NASH and suggests that it may make a significant 
contribution to the hepatocyte lipoapoptosis observed in this disease. 
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Figure 5.2: Caspase-2 is significantly upregulated in patients with NASH and 
in mice fed an MCD diet 
 
Figure 5.2: A. Representative caspase-2 immunohistochemistry (brown) in livers from WT 
mice fed regular chow (control diet) or methionine choline deficient (MCD) diet.  B. Western 
blot analysis of livers of WT mice fed as above.  Each lane represents an individual mouse 
sample and tubulin serves as a loading control.  C. Representative caspase-2 
immunohistochemistry (brown) in a healthy human liver and in NASH patients (n= 2).   
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5.2.3 Caspase-2 KO mice are protected from MCD diet-induced 
apoptosis and fibrosis 
After observing significant upregulation of caspase-2 in multiple NASH settings, 
we aimed to determine whether the loss of caspase-2 would offer protection against 
hepatocyte apoptosis and the consequential liver fibrosis induced by this disease.  To 
test this, we subjected WT and caspase-2 KO mice to either a control or MCD diet for 8-
weeks and assayed hepatocyte apoptosis using TUNEL staining.  Caspase-2 KO mice 
showed significantly fewer TUNEL positive cells following the administration of the 
NASH-inducing diet (Figure 5.3 A and B).  These data demonstrate that caspase-2 KO 
mice are protected from hepatocyte apoptosis and suggest that caspase-2 is necessary to 
elicit the full lipoapoptotic response induced by the MCD diet.   
Since hepatocyte lipoapoptosis contributes to an increased risk of liver fibrosis, 
specifically by triggering the myofibroblastic transformation of HSCs through the 
phagocytosis of apoptotic bodies, evaluating markers of liver fibrosis can be helpful in 
assessing the contribution of caspase-2 to NASH progression.  Therefore, we assessed 
HSC activation using α-SMA as a marker of myofibroblastic transformation.  We 
performed immunohistochemistry on the livers of both WT and caspase-2 KO mice and 
found that caspase-2 KO mice showed reduced α-SMA staining, suggesting a reduced 
activation of HSCs (Figure 5.4 A).   
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Figure 5.3: Caspase-2 KO mice are protected from MCD diet-induced apoptosis 
 
To determine if the reduced accumulation of α-SMA was accompanied by 
changes in liver fibrosis, liver sections were stained with Sirius Red and collagen 1α1 to 
evaluate the abundance of collagen fibrils.  Consistent with there being a reduced 
activation of HSCs, caspase-2 KO mice showed a reduced accumulation of Sirius Red-
stained fibrils and a reduced expression of collagen 1α1 (Figure 5.4 B and C).  These data 
are furthered supported by a reduction in collagen 1α1 mRNA, as determined by QRT-
PCR analysis (Figure 5.4 C).  Taken together, these data suggest that loss of caspase-2 
leads to a reduction in NASH-associated fibrogenesis.  This reduction, combined with 
the decreased HSC activation, suggests that caspase-2 KO mice are protected from 
Figure 5.3: A. Representative TUNEL assays of liver sections from WT or caspase-2 KO mice 
fed a high fat diet (control) or a methionine choline deficient (MCD) diet.  Arrows indicate 
TUNEL-positive cells in control livers.  B. TUNEL-positive cells were counted and graphed as 
mean ± SEM (n=3 mice/group).  
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hepatic lipoapoptosis induced by the MCD diet and identify caspase-2 as a potential 
therapeutic target for preventing the progressive fibrogenesis observed in NASH. 
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Figure 5.4: Caspase-2 KO hepatocytes are protected from MCD diet-induced fibrosis 
  
Figure 5.4: A. Representative αSMA immunohistochemistry (brown) of liver sections from 
WT or caspase-2 KO mice fed a high fat diet (control) or a methionine choline deficient (MCD) 
diet.  B. Sirius red staining of collagen fibrils. C. Collagen 1α1 immunohistochemistry (brown) 
and qRT-PCR analysis of liver RNA normalized to expression in HF diet-fed WT mice and 
expressed as mean ± SEM. 
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5.3 Discussion 
Previously, we demonstrated that caspase-2 is activated in response to an over-
abundance of long-chain fatty acids and that the loss of caspase-2 could protect 
mammalian cell lines from lipotoxicity in vitro.  In order to determine the therapeutic 
significance of these findings, experiments evaluating the importance of caspase-2 in an 
in vivo model of lipotoxicity needed to be performed.  In this chapter, we treated 
caspase-2 KO mice with a diet deficient in methionine and choline, which induces severe 
liver steatosis, and evaluated the degree of disease protection as compared with control 
mice.  We first demonstrated that caspase-2 KO hepatocytes are protected from lipid-
induced cell death in vitro, just as we observed in mammalian cell lines depleted of 
caspase-2 with siRNA.  Interestingly, we observed increased expression of caspase-2 in 
the livers of mice fed the MCD diet.  These findings were of particular interest when we 
noted an increase in caspase-2 expression in NASH patients.  Lastly, we found that 
caspase-2 KO mice administered the NASH-inducing diet were protected from 
apoptosis and fibrosis, suggesting that caspase-2 is critical regulator of lipid-induced 
hepatocyte cell death in NASH.   
5.3.1 Caspase-2 expression is significantly increased in hepatocytes 
in NASH 
In this study, we showed that caspase-2 expression is significantly increased in 
both patient samples and our mouse model of NASH.  Increased expression of caspase-2 
was largely detected in fatty hepatocytes and appeared to be enriched near fibrotic 
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septa.  Such a distribution suggests that caspase-2 might be triggering apoptosis and 
consequently, activation of fibrogenesis in the surrounding areas.  While we have had 
little success detecting elevations of caspase-2 protein in mammalian cell lines treated 
with LCFAs, several recent publications have noted increased expression of the protease 
following high fat feeding in vivo (Jobgen et al., 2009; Miller et al., 2014).  It is possible 
that the observed increase in caspase-2 protein is an event which requires whole tissue 
signaling triggered by physiological lipid accumulation.  Thus, it is possible that our cell 
culture model of exogenous LCFA supplementation doesn’t fully recapitulate the 
lipotoxic stress triggered in vivo and thus, we are unable to observe similar changes in 
caspase-2 protein levels.   
Although historically, changes in the level of caspase-2 have not been shown to 
promote enzyme activation, recent findings have suggested that increased levels of 
caspase-2 stemming from translational upregulation are, indeed, required for activation 
of the caspase, at least in the setting of ER stress (Upton et al., 2012).  The prevailing 
model is that ER stress triggers activation of IRE1α, an RNase, which causes rapid decay 
of select microRNAs that translationally repress caspase-2.  Degradation of these 
microRNAs lifts this repression, resulting in increased translation and thus, expression 
of caspase-2.  Interestingly, IRE1α has been shown to be activated in NASH and its 
activation has been shown to correlate with histologic disease severity (Puri et al., 2008).  
Having previously been implicated in the development of cellular injury in NASH, it is 
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tempting to hypothesize that activation of IRE1α might be initiating cell death via 
caspase-2 stabilization.  We are actively trying to investigate this possibility by 
performing studies that will measure the level of target microRNAs following MCD diet 
treatment.  If these studies prove to be fruitful, microRNA regulation of caspase-2 could 
be exploited for therapeutic purposes.   
5.3.2 Potential mechanism for caspase-2 activation in NASH 
While we have provided extensive evidence that the over-accumulation of lipids 
can trigger activation of caspase-2, we have failed to uncover the mechanism by which 
this activation occurs.  Previously, our laboratory demonstrated that caspase-2 could be 
suppressed through CaMKII mediated phosphorylation at serine-135 in Xenopus egg 
extracts (see figure 1.5) (Nutt et al., 2005).  Recent data has suggested that the activity of 
CaMKII can be modulated by the availability of CoA (McCoy et al., 2013).  The 
accumulation of fatty acids can reduce the free CoA/acyl-CoA ratio, resulting in a 
decreased availability of free CoA.  Reductions in free CoA could result in a reduced 
activation of CaMKII, which could make caspase-2 more susceptible to activation 
through reduced phosphorylation at serine-135.  Studies to investigate the relevance of 
this mechanism should evaluate the level of caspase-2 phosphorylation and CaMKII 
activation following the induction of lipotoxicity in both cell and animal models.   
  
111 
5.3.3 Caspase-2 is a favorable therapeutic target in preventing 
apoptosis and fibrosis in NASH progression 
The data presented in this chapter bolster the role of caspase-2 in lipid-induced 
cell death by validating its importance in an animal model of NASH.  We confirmed that 
caspase-2 is an important initiator of lipoapoptosis in NASH by demonstrating that KO 
mice had significantly fewer TUNEL-positive cells in mice fed a NASH-inducing diet.  
Moreover, caspase-2 KO mice had less activation of HSC and less fibrosis, suggesting 
that caspase-2 is an attractive therapeutic target for blocking apoptosis, preventing 
fibrosis, and slowing the progression of NAFLD. 
Since there are currently no therapies to halt NAFLD progression, our findings 
warrant further investigation.  One potential drawback to targeting caspase-2 directly in 
patients with NAFLD would be that such a treatment could potentially increase their 
risk of tumor development.  For example, although caspase-2 KO mice fail to show an 
increased susceptibility of tumorigenesis, loss of caspase-2 in combination with another 
tumor suppressor, such as the ataxia telangiectasia mutated (ATM) kinase which 
controls the DNA damage pathway, can result in an increased incidence of tumor 
development (Bergeron et al., 1998; Puccini et al., 2013).  Since preventing apoptosis and 
fibrosis would likely require prolonged treatment so patients have time to reduce their 
lipid levels through diet and exercise, there is a chance that patients could be put at an 
increased risk of tumor development or progression.  While we found no evidence that 
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inhibiting caspase-2 was unsafe in our mouse model of NASH, future studies should 
evaluate the significance of the aforementioned risks.   
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6. Conclusion and perspectives 
With the prevalence of obesity and metabolic syndrome rising sharply world-
wide, it has become increasingly important to define the molecular mechanisms 
underlying the pathogenesis and progression of diseases associated with lipid-induced 
cytotoxicity.  Multiple studies have focused on identifying the specific lipid species that 
triggers lipoapoptosis and there is an overwhelming consensus the free fatty acids are 
the toxic offenders.  The lipotoxic effects of free fatty acids are complex, since they can 
promote ER stress as well as trigger mitochondrial permeabilization, cytochrome c 
release, and executioner caspase activation.  Although the role of the mitochondria in 
lipoapoptosis was well established, little attention had been given to the pro-death 
signaling pathways functioning upstream of the mitochondria.  Work from this 
dissertation contributes to a better understanding of the early steps of lipoapoptosis, 
specifically identifying caspase-2 as the initiator, and should help to identify novel 
therapeutic approaches for this disease process.   
6.1 Lipid accumulations promote the activation of caspase-2 in 
Xenopus egg extract 
In Chapter 3 of this dissertation, we describe metabolomic profiling of Xenopus 
egg extract.  The link between metabolism and caspase-2 was initially discovered by our 
lab and we have described a detailed molecular mechanism for how metabolism can 
influence caspase-2 modification and activation (Andersen et al., 2011; Nutt et al., 2009; 
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Nutt et al., 2005).  While these studies lead to the hypothesis that Xenopus egg extract 
apoptosis occurs in response to metabolic starvation, there were conflicting data 
between this hypothesis and the nutrient-sensitive metabolic enzymes regulating 
caspase-2 modification.  Thus, we aimed to determine the true metabolic stress 
triggering caspase-2 activation in these extracts.    
Our metabolomics analysis revealed that Xenopus egg extracts experience a 
dramatic increase in LCFA metabolites prior to caspase activation.  Interestingly, 
supplementation of the extract with metabolic intermediates or inhibitors that are able to 
block caspase-2 activation also blocked the accumulation of LCFAs.  This data, although 
correlative, suggested that the buildup of lipids might be the metabolic stress triggering 
caspase-2 activation.  To test this hypothesis, we attempted to overcome the metabolic 
suppression provided by extract supplementation and found that exogenous addition of 
the saturated LCFA, palmitate, could not only overcome caspase-2 inhibition but could 
accelerate it.  These data heavily implicated LCFA accumulation in the activation of 
caspase-2.   
Although strictly speculative, we have provided a hypothesis for the dramatic 
metabolic changes that were observed upon extract incubation.  These speculations are 
based on the lack of mitochondrial respiration that was evident following measurement 
of mitochondrial oxygen consumption.  The failure of mitochondria to utilize oxidative 
phosphorylation would results in several of the phenotypes we have observed, 
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including: (1) insufficient supply of oxidized electron carriers (i.e., decrease in the 
NAD+/NADH ratio) (2) increases in succinate, since succinate dehydrogenase 
participates in both the electron transport chain and the TCA cycle and (3) a decrease in 
anaplerotic substrates, mainly oxaloacetate, resulting in the accumulation of acetyl-CoA 
and pyruvate.  The inefficient flux of substrates through glycolysis and the TCA cycle 
without the ability to regenerate NAD+ will lead to a redox imbalance, resulting in 
increased levels of NADH.  We suspect that the accumulation of NADH results in the 
accumulation of LCFAs by both increasing fatty acid elongation (driven by increasing 
acetyl-CoA and NADH levels) and decreasing beta-oxidation (which would be inhibited 
by increasing NADH levels).   
Interestingly, we have previously demonstrated that the exogenous addition of 
NAD+ can protect against caspase-2 activation in this system (Andersen et al., 2011).  
The mechanism for this suppression was suggested to be through Sirt1-mediated 
deacetylation of 14-3-3ζ, which enables this protein to bind to an inhibitory 
phosphorylation site on caspase-2 (Ser135) and protect it against dephosphorylation (See 
section 1.2.5.2 for a review).  It would be interesting to know whether addition of this 
oxidized electron carrier also protects against caspase-2 activation by stabilizing the 
redox state of the extract and consequently, blocking the accumulation of long-chain 
lipids.   It is tempting to speculate that changes in cellular redox status, which can 
trigger caspase-2 dephosphorylation through the loss of 14-3-3 binding because of a 
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decrease in sirt1 activity, actually sensitize caspase-2 to activation by LCFA 
accumulations through the removal of an inhibitory phosphorylation.  
Moreover, it is still unclear how the buildup of LCFAs triggers the activation of 
caspase-2 in egg extract.  Can LCFAs directly promote the activation of caspase-2 or do 
they mediate their toxicity through secondary pathways, via ceramide synthesis or the 
generation of ER stress?  Although we initially focused on the translational aspects of 
this research, determining the relevance of LCFA-induced caspase-2 activation in cell 
and animal models, it would be helpful to know the mechanism of activation in this 
setting, especially for the purposes of therapeutic intervention.  Fortunately, the 
Xenopus egg extract system is ideal for determining whether LCFAs can directly 
promote caspase-2 activation in the absence of any membrane components.  As 
mentioned in the introduction, we have the ability to make pure cytosolic extracts, 
devoid of any membranes (i.e., ER, Golgi, mitochondria), which we can treat with 
palmitate to determine whether they are sufficient to activate caspase-2 in this setting.  
Additionally, we can add back individual membrane fractions, including purified 
mitochondria or ER membranes to determine which, if any of these membrane fractions, 
are necessary for exerting the toxic signaling events that promote caspase-2 activation. 
Future research efforts will be put toward understanding how the accumulation of 
LCFAs can promote caspase-2 activation in egg extract. 
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Finally, our studies from the Xenopus egg extract model system suggested that 
the buildup of LCFA metabolites could trigger the activation of caspase-2.  Our 
metabolomic studies revealed a positive correlation between lipid accumulation and 
caspase-2 activation, which we felt warranted further investigation.  Therefore, we 
looked specifically at whether caspase-2 could function as a more general initiator of cell 
death in response to lipotoxicity in mammalian cell system and this data is discussed 
below. 
6.2 Caspase-2 regulates lipoapoptosis in mammalian cells 
In Chapter 4 of this dissertation, we extend our findings from the Xenopus model 
system to mammalian somatic cells.  We aimed to determine whether caspase-2 was 
activated in response to an over-accumulation of LCFAs through multiple approaches.  
As detailed in section 1.2.3, caspase-2 activity can be assessed by a number of different 
assays and differences among these methodologies have contributed to controversy 
surrounding caspase-2-activating stimuli.  Because the caspase-2 research field lacks an 
efficient assay for evaluating caspase-2 activation, we performed several assays, 
including the depletion of caspase-2, to determine its importance. 
Using an in vitro caspase-2 activity assay that measures VDVAD cleavage, we 
found that caspase-2 activity increased significantly following treatment with the 
saturated LCFA, palmitate.  We also observed processing of the proenzyme by western 
blot following palmitate treatment.  Importantly, we verified caspase-2 is activated by 
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recruitment to a HMW complex and that only the HMW fractions containing caspase-2 
exhibited enzymatic activity.  Finally, we confirmed the activation of caspase-2 
following palmitate treatment in situ using BiFC.   
Once we knew that palmitate could activate caspase-2, we aimed to determine 
whether caspase-2 was required for the cell death induced by this saturated LCFA.  We 
observed that the depletion of caspase-2 by siRNA significantly protected 293T cells 
against lipoapoptosis, suggesting that caspase-2 is necessary for full activation of the 
apoptotic cascade in response to palmitate toxicity.  Delving further into caspase-2-
induced lipotoxicity, we confirmed that only saturated fatty acids induced cell death 
and that this cell death was dependent on caspase-2.  Interestingly, the activation of 
palmitate via acyl-CoA formation was required for its toxicity and we have ongoing 
studies evaluating how saturated LCFAs and their respective acyl-CoA derivatives 
induce caspase-2 activation.   
To evaluate the relevance of our findings in a more physiologic setting, we tested 
whether caspase-2 was necessary for hepatocyte lipoapoptosis.  Interestingly, 
lipoapoptosis plays an important role in the pathophysiology of liver disease, 
contributing to the development and progression of NAFLD.  Our data show that 
depletion of caspase-2 by siRNA significantly protects normal and transformed 
hepatocyte cell lines from saturated fatty acid induced cell death.  These findings 
demonstrate that caspase-2 is necessary for hepatocytes lipoapoptosis and suggest that 
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caspase-2 may be a useful therapeutic target.  At present, there are no effective therapies 
for halting the progression of NAFLD and thus, therapeutic targeting of caspase-2 may 
prove useful.   
Although we know that caspase-2 is activated following its recruitment into a 
HMW complex in LCFA-induced cell death, attempts to identify its activation platform 
have, thus far, been unsuccessful.  Moreover, we have had mixed results on the 
importance of the adaptor protein, RAIDD, in these studies.  Despite these difficulties, 
we continue to try to define the activation platform necessary for caspase-2 activation in 
lipotoxicity.  Encouragingly, our laboratory has recently developed a new methodology 
for identifying caspase-2 binding partners using a green fluorescent protein (GFP)-trap 
assay along with our stable BiFC expressing cells.  Following its activation in situ, 
caspase-2 is immunoprecipitated by pulling down on the dimerized fragments of venus 
using GFP-trap.  Initial experiments have been successful in isolating specific caspase-2 
binding partners and thus, we aim to use this novel assay to identify the caspase-2 
activation platform in lipoapoptosis.  Insight into the molecular mediators of caspase-2 
activation could reveal a favorable target for therapeutic intervention.   
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While our initial intent in performing these studies was to determine whether 
our findings from the Xenopus egg extract were applicable to mammalian cells, we have 
struggled to evaluate the relevance of our metabolically-regulated post-translational 
modification mechanism (Figure 1.5) in the mammalian cell setting.  Caspase-2 
phosphorylation at the conserved serine residue in mammalian cells (serine 164) appears 
to be low in abundance.  As such, we have had difficult detecting the binding between 
caspase-2 and 14-3-3ζ, the small acidic protein which binds this phospho-site to inhibit 
dephosphorylation.  Since this mechanism of caspase-2 regulation was originally 
identified in egg extracts treated with glucose-6-phosphate, it may well be that this 
mechanism is not conserved or that it is only applicable in mammalian cells under 
certain physiological conditions, which we have not yet determined.  Future studies will 
need to evaluate the importance of this phosphorylation in mammalian cells before we 
can determine its relevance in the lipoapoptotic activation of caspase-2.  Nevertheless, 
we would hypothesize that high levels of cellular lipids would result in inhibition of 
Sirt1, a regulator of 14-3-3ζ acetylation and binding to caspase-2, by decreasing cellular 
NAD+/NADH ratios via enhanced beta-oxidation.  Thus, even if caspase-2 
phosphorylation at serine 164 were found to be important in mammalian cells, we 
suspect that increases in intracellular lipids loads would remove this post-translational 
inhibition via changes in Sirt1 activity.   
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6.3 The loss of caspase-2 protects against lipoapoptosis and 
fibrosis in a mouse model of NASH 
In Chapter 5 of this dissertation, we translated our findings from mammalian cell 
line to an in vivo mouse model of lipotoxicity.  Since lipoapoptosis has been implicated 
as a key driver of NASH pathogenesis and progression, we aimed to determine whether 
caspase-2 plays a role in this process (Feldstein et al., 2003).  Importantly, hepatocyte 
apoptosis strongly influences the severity of liver fibrosis in NASH, resulting in the 
transformation of HSCs to a myofibroblstic state, where they begin secreting collagen 
and can promote liver cirrhosis.  The inhibition of lipoapoptosis is one potential 
therapeutic option for slowing the progression of NAFLD to NASH and thus, we were 
interested in determining whether caspase-2 could regulate lipotoxicity in vivo.   
To investigate this possibility, we first tested whether hepatocytes derived from 
caspase-2 KO mice were protected from saturated fatty acid induced cell death in vitro.  
We found that caspase-2 KO hepatocytes underwent less cell death when treated with 
palmitate in culture.  Unexpectedly, we found that caspase-2 protein expression was 
significantly increased in the livers of mice fed a NASH-inducing diet (MCD diet) and it 
appeared that this increased expression occurred mainly in fatty hepatocytes.  Given this 
finding, we evaluated caspase-2 expression in the livers of patients who had been 
diagnosed with NASH and encouragingly, we observed that its expression was 
dramatically increased as well.  These findings further substantiate the relevance of our 
NASH-inducing animal model for the study of NAFLD pathogenesis.  
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Finally to determine whether the loss of caspase-2 would offer protection against 
NASH progression, we treated caspase-2 KO cells with the MCD diet and found that 
they were protected against hepatocyte lipoapaoptosis, as shown by a decrease in 
TUNEL positive cells.  Moreover, in comparing caspase-2 KO with control mice, we 
observed a decrease in HSC transformation and fibrotic staining.  These data suggest 
that caspase-2 KO mice are also protected against the fibrogenesis prompted by 
apoptotic cells.  Taken together, these data demonstrate a role for caspase-2 in inducing 
the cell death of hepatocytes in NASH-induced lipoapoptosis.   
At present, there are no proven effective therapies for halting NASH progression.  
Our work suggests that targeting caspase-2 and/or its regulators may be used as a 
potential therapeutic strategy.  Indeed, recent studies have shown moderate success of 
pan-caspase inhibitors on NAFLD/NASH symptoms in both patient and animal models 
(Ratziu et al., 2012; Witek et al., 2009).  Excitingly, our data suggest that an inhibitor 
which more specifically targets caspase-2 may enhance the effectiveness of caspase-
targeted therapies.  The loss of this apical initiator caspase doesn’t appear to 
compromise viability in a knock-out setting and thus, caspase-2 is an attractive 
therapeutic target for both blocking apoptosis and maintaining mitochondrial integrity 
in NASH.  We hope that our work will contribute to the development of novel therapies 
for the treatment of this disease. 
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6.4 Concluding Remarks 
The data presented in this dissertation have advanced our understanding of 
caspase-2, demonstrating a novel role of the pro-apoptotic initiator caspase in lipid-
induced apoptosis.  Using an unbiased metabolomics approach, we discovered that the 
activation of caspase-2, the initiator of apoptosis in Xenopus egg extract, was associated 
with an accumulation of LCFA metabolites.  Metabolic treatments that blocked the 
build-up of LCFA metabolites also potently inhibited caspase-2.   The caspase-
suppressive effect of such metabolic treatments could be overridden by supplementing 
the extract with the saturated LCFA, palmitate, suggesting that the buildup of LCFAs 
could trigger caspase-2 activation in this system.   
Importantly, we have extended these findings to the mammalian somatic cell 
system, where we have demonstrated that caspase-2 is activated following palmitate 
treatment.  We demonstrated that caspase-2 was activated by both cleavage of the 
preferred caspase-2 substrate, VDVAD, as well as proteolytic processing of the caspase-2 
proenzyme.  Furthermore, we also discovered that caspase-2 was activated by 
recruitment to a HMW complex following palmitate treatment and that caspase-2 was 
required for full activation of palmitate-induced cell death.  Delving further into 
caspase-2-induced lipotoxicity, we confirmed that only saturated fatty acids induced cell 
death and that this cell death was dependent on caspase-2.  Interestingly, as has 
previously been observed in other cells types, palmitate-induced cytotoxicity was not 
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dependent on ROS, ceramides, or oxidative LCFA catabolism in 293T cells (Hardy et al., 
2003; Kim et al., 2008; Staiger et al., 2006).  Rather, the activation of palmitate via acyl-
CoA formation was required to induce cell death.  Taken together, these findings reveal 
a conserved, critical role for caspase-2 in mediating LCFA-induced lipoapoptosis.   
Finally, to demonstrate the therapeutic significance of our findings, we evaluated 
the importance of caspase-2 in an in vivo model of lipotoxicity.  We first demonstrated 
that caspase-2 KO hepatocytes are protected from lipid-induced cell death in vitro, just 
as we observed in mammalian cell lines depleted of caspase-2.  Interestingly, we 
observed an increase in caspase-2 expression in the livers of wild-type mice following 
the administration of a NASH-inducing diet.  These findings are of particular 
importance, as caspase-2 expression is also increased in patients diagnosed with NASH.  
Most importantly, we demonstrated that caspase-2 KO mice are protected from 
apoptosis and fibrosis when fed a NASH-inducing diet, suggesting that caspase-2 is 
major regulator of hepatocyte lipoapoptosis.  These data suggest that caspase-2 is an 
attractive therapeutic target for blocking apoptosis, preventing fibrogenesis, and 
slowing the progression of NAFLD and we look forward to following up on these 
studies.
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